Anti-CD200r1 antibody and use thereof

A novel antibody targeting CD200R1 with specific CDR sequences and its application in a CAR for immune cells addresses the limitations of existing antibodies, achieving superior immunosuppressive and inflammatory response effects for treating immune and inflammatory diseases.

WO2024248532A1PCT designated stage expired Publication Date: 2024-12-05AIMED BIO INC
View PDF 17 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/007469
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Existing anti-CD200R1 agonist antibodies have limitations in binding non-competitively to the same domain and achieving superior immunosuppressive and inflammatory response effects compared to existing antibodies.

Method used

Development of a novel antibody or antigen-binding fragment specifically binding to CD200R1, comprising specific heavy and light chain CDR sequences, and its use in a chimeric antigen receptor (CAR) for immune cells to enhance immunosuppressive effects.

Benefits of technology

The novel antibody exhibits superior immunosuppressive and inflammatory response effects, providing enhanced therapeutic potential for immune and inflammatory diseases by specifically targeting CD200R1.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024007469_05122024_PF_FP_ABST
    Figure KR2024007469_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to an anti-CD200R1 antibody or an antigen-binding fragment thereof; a nucleic acid encoding same; an expression vector comprising the nucleic acid; a host cell having the nucleic acid or the expression vector introduced thereinto; a method for preparing the antibody or an antigen-binding fragment thereof; a bi- or multi-specific antibody comprising the antibody or an antigen-binding fragment thereof; a chimeric antigen receptor (CAR) comprising the antibody or an antigen-binding fragment thereof; an immune cell expressing the antibody or an antigen-binding fragment thereof or a chimeric antigen receptor comprising same; an immunosuppressive composition comprising the antibody or an antigen-binding fragment thereof, and a medicinal use.
Need to check novelty before this filing date? Find Prior Art

Description

Anti-CD200R1 antibodies and uses thereof

[0001] The present invention relates to an anti-CD200R1 antibody or an antigen-binding fragment thereof, a nucleic acid encoding the same, an expression vector comprising the nucleic acid, a host cell into which the nucleic acid or the expression vector has been introduced, a method for producing the antibody or an antigen-binding fragment thereof, a bispecific or multispecific antibody comprising the antibody or an antigen-binding fragment thereof, a chimeric antigen receptor (CAR) comprising the antibody or an antigen-binding fragment thereof, an immune cell expressing the antibody or an antigen-binding fragment thereof or a chimeric antigen receptor comprising the same, an immunosuppressive composition comprising the antibody or an antigen-binding fragment thereof, and a pharmaceutical use thereof.

[0002]

[0003] CD200R1 is known to be a receptor that can bind precisely due to its structural similarity to the CD200 protein, one of the type 1 cell membrane glycoproteins. CD200R, a member of the Ig superfamily (IgSF), is a checkpoint receptor that suppresses immune cell activation and is composed of two IgSF domains, one transmembrane domain, and a cytoplasmic domain. Two isoforms of human CD200R are known, CD200R1 and CD200R2, and four isoforms of mouse CD200R are known, CD200R1, CD200R2, CD200R3, and CD200R4. In vivo, CD200 ligand binds only to the N-terminal Ig V-type domain of CD200R1 and induces a significant immunosuppressive response (Int J Physiol Pahtophysiol Pharmacol 2019;11(6):297-309). In particular, CD200R1 is known to transmit signals better than other forms of CD200R because it has a long cytoplasmic domain.

[0004] When CD200R1 is activated, phosphorylation of the Dok2 adaptor protein occurs, inducing an intracellular signaling cascade that suppresses target cell proliferation and immune responses. CD200R1 is known to be highly expressed in myeloid-derived mononuclear cells such as macrophages, dendritic cells, and mast cells. In addition, CD200R1 is also expressed in large amounts in immune cells such as eosinophils and neutrophils, which induce innate immunity, and thus has the potential to be developed as a treatment for diseases such as atopic dermatitis with allergic pathology and sinusitis with nasal polyps. In addition, analysis of human genome data has reported a direct correlation between the CD200R1 and Dok2 protein genes and the heritability of atopic dermatitis (J Allergy Clin Immunol, Volume 145, Number 4). Furthermore, the CD200R1 pathway may be a target for neuroinflammatory diseases such as multiple sclerosis, stroke, and Parkinson's disease.

[0005] Anti-CD200R1 antibodies targeting CD200R1 are divided into agonists, which suppress immune responses, and antagonists, which activate immune responses. First, the 23ME-00610 (23AndMe) monoclonal antibody, an antagonist that inhibits signaling through anti-CD200R1, has begun phase 1 / 2 clinical trials, and its efficacy is being confirmed in various cancers, including clear cell renal cell carcinoma, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and neuroendocrine tumors (Clinicaltrials, NCT05199272). The drug is currently under development with a mechanism of action that maximizes the anticancer effect mediated by T cells by blocking the signaling that suppresses immune responses.

[0006] Meanwhile, anti-CD200R1 agonists can enhance the immunosuppressive effect of CD200 in existing body tissues. In WO 2015 / 057906, the CD200R agonist antibody (H2RM147, Janssen) was shown to competitively bind to human CD200, and in US 2020 / 0087395, the CD200R agonist antibody (I-4P, Eli Lilly) was developed to overcome this by binding to a different domain of the CD200R1 protein, and thus each has its own limitations.

[0007] Under this technical background, the present inventors have made great efforts to overcome the limitations of the existing CD200R1 agonist antibodies and develop an anti-CD200R1 agonist antibody with superior efficacy. As a result, by utilizing various unique screening technologies owned by the applicant, the inventors have developed an antibody that binds to the same domain while non-competitively binding to human CD200, and confirmed that the antibody exhibits superior immune suppression and inflammatory response suppression effects than the existing CD200R1 antibodies, thereby completing the present invention.

[0008]

[0009] Summary of the invention

[0010] The purpose of the present invention is to provide a novel antibody or antigen-binding fragment thereof that specifically binds to CD200R1 (CD200 Receptor 1), and uses thereof.

[0011] Another object of the present invention is to provide a nucleic acid encoding the antibody or an antigen-binding fragment thereof.

[0012] Another object of the present invention is to provide a recombinant expression vector containing the nucleic acid or a cell into which the nucleic acid or expression vector has been introduced.

[0013] Another object of the present invention is to provide a method for producing an antibody or an antigen-binding fragment thereof that specifically binds to CD200R1.

[0014] Another object of the present invention is to provide a bispecific / multispecific antibody comprising the antibody or an antigen-binding fragment thereof.

[0015] Another object of the present invention is to provide a chimeric antigen receptor (CAR) comprising the scFv of the antibody as an antigen binding site of the extracellular domain, an immune cell into which the chimeric antigen receptor has been introduced, and a use thereof.

[0016] Another object of the present invention is to provide an immunosuppressive composition comprising the antibody or an antigen-binding fragment thereof, the bispecific or multispecific antibody, the chimeric antigen receptor, or the immune cell.

[0017] Another object of the present invention is to provide a composition for preventing or treating an immune disease or inflammatory disease, comprising the antibody or an antigen-binding fragment thereof, the bispecific or multispecific antibody, the chimeric antigen receptor, or the immune cell.

[0018]

[0019] To achieve the above purpose, the present invention provides an antibody or antigen-binding fragment thereof that specifically binds to CD200R1, comprising:

[0020] A heavy chain CDR1 comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 8, SEQ ID NOs: 100 to 103, and SEQ ID NO: 158;

[0021] A heavy chain CDR2 comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 9 to 21, SEQ ID NOs: 104 to 109, and SEQ ID NO: 159;

[0022] A heavy chain CDR3 comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 22 to 35, SEQ ID NOs: 110 to 115, SEQ ID NOs: 160, SEQ ID NOs: 172 and 173;

[0023] A light chain CDR1 comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 36 to 47, SEQ ID NOs: 116 to 122, SEQ ID NOs: 161, SEQ ID NOs: 192, and SEQ ID NOs: 193;

[0024] A light chain CDR2 comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 48 to 58, SEQ ID NOs: 123 to 127, SEQ ID NO: 162, and SEQ ID NO: 194; and

[0025] A light chain CDR3 comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 59 to 70, SEQ ID NOs: 128 to 134, SEQ ID NOs: 163, SEQ ID NOs: 174 to 183, SEQ ID NOs: 195, and SEQ ID NOs: 196.

[0026] The present invention also provides a nucleic acid encoding the antibody or an antigen-binding fragment thereof.

[0027] The present invention also provides a recombinant expression vector comprising the nucleic acid.

[0028] The present invention also provides a host cell transfected with the recombinant expression vector.

[0029] The present invention also provides a method for producing an antibody or an antigen-binding fragment thereof that specifically binds to CD200R1, comprising the steps of culturing a host cell to produce an antibody; and isolating and purifying the produced antibody.

[0030] The present invention also provides a bispecific / multispecific antibody comprising the antibody or an antigen-binding fragment thereof.

[0031] The present invention also provides a chimeric antigen receptor (CAR) comprising the antigen-binding fragment.

[0032] The present invention also provides an immune cell comprising the chimeric antigen receptor (CAR).

[0033] The present invention also provides a composition comprising the antibody or antigen-binding fragment thereof, the bispecific or multispecific antibody, the chimeric antigen receptor or the immune cell.

[0034] The present invention also provides a composition for preventing or treating an immune disease or inflammatory disease, comprising the antibody or antigen-binding fragment thereof, the bispecific or multispecific antibody, the chimeric antigen receptor and / or the immune cell.

[0035] The present invention also provides the use of the antibody or antigen-binding fragment thereof, the bispecific or multispecific antibody, the chimeric antigen receptor or the immune cell for the prevention or treatment of an immune disease or an inflammatory disease.

[0036] The present invention also provides the use of the antibody or antigen-binding fragment thereof, the bispecific or multispecific antibody, the chimeric antigen receptor or the immune cell for the manufacture of a medicament for the prevention or treatment of an immune disease or an inflammatory disease.

[0037] The present invention also provides a method for preventing or treating an immune disease or an inflammatory disease, comprising administering to a subject the antibody or an antigen-binding fragment thereof, the bispecific or multispecific antibody, the chimeric antigen receptor and / or the immune cell.

[0038]

[0039] Figure 1 shows the results of screening human CD200R1 binding antibodies using phage display.

[0040] Figure 2 shows the cross-linking of human CD200R1 and mouse CD200R1 using clones discovered by phage display using ELISA.

[0041] Figure 3 shows the results of confirming whether clones discovered by phage display through ELISA competitively bind to CD200 protein.

[0042] Figure 4 shows the results of screening for human CD200R1 binding antibodies using hybridomas.

[0043] Figure 5 shows a schematic diagram of humanization engineering of the P001017 antibody.

[0044] Figure 6 shows the results of analyzing the binding ability of human CD200R1 of humanized antibody clones of the P001017 antibody through ELISA.

[0045] Figure 7 shows the results of in silico humanness analysis for the humanized antibody P001017, P001018.

[0046] Figure 8 shows the results of ELISA human CD200R1 binding ability analysis of affinity-improved variants of the P001018 humanized antibody.

[0047] Figure 9 shows the results of confirming the cell binding ability of the affinity-improved variant for the P001018 humanized antibody in HH cells.

[0048] Figure 10 shows the results of ELISA to confirm the binding ability of P001017, P001018 (humanized antibody), and affinity-improved P001018v26 to human CD200R1 and mouse CD200R1 in IgG1 and IgG4 forms.

[0049] Figure 11 shows the results of confirming the cross-binding ability of the clones discovered in the embodiment of the present invention to human CD200RLa and monkey CD200RLa, which are immune activation receptors, through ELISA.

[0050] Figure 12 shows that antibodies discovered in an embodiment of the present invention bind differently to the human-mouse HM hybrid domain and the mouse-human MH hybrid domain.

[0051] Figure 13 shows the results of cell binding ability analysis in Jurkat-CD200R, HH, a CD200R overexpressing cell line, in the IgG1 form of clones discovered in an example of the present invention.

[0052] Figure 14 shows the results of cell binding ability analysis in Jurkat-CD200R and HH, which are CD200R overexpressing cell lines, by modifying the clones discovered in the examples of the present invention with IgG4 and LALAPG mutations, respectively.

[0053] Figure 15 shows the results of ELISA analysis of P001009 and variants that underwent antibody amino acid optimization; analysis of binding ability to human, mouse, and monkey CD200R1.

[0054] Figure 16 shows the results of SPR analysis of P001009 and its variants that underwent antibody amino acid optimization: analysis of binding ability to human and monkey CD200R1.

[0055] Figure 17 shows the results of cell binding ability analysis of P001009 and variants that underwent antibody amino acid optimization.

[0056] Figure 18 shows microscopic photographs of cells treated with LPS to induce cellular inflammatory responses to analyze the ability to suppress inflammatory cytokines in a U937-CD200R1 overexpressing cell line. Figure 18A shows U937-CD200R1 cells not treated with LPS, and Figure 18B shows U937-CD200R1 cells treated with 1 μg / ml of LPS.

[0057] Figure 19 shows the results of confirming the inflammatory cytokine suppression ability of P001009 and P001009v1 antibodies in the U937-CD200R1 overexpressing cell line.

[0058] Figure 20 shows the results of an analysis of the extent to which Dok2 protein phosphorylation is induced by the efficacy of P001009 and P001009v1 antibodies in a Jurkat-CD200R1 overexpressing cell line.

[0059] Figure 21 shows the flow chart of ex vivo screening using non-polyposis patient specimens (top); and the results of establishing a system for evaluating cytokine inhibition using a positive control drug.

[0060] Figure 22 shows the results for P001009v1, which showed superior cytokine suppression compared to existing treatments in three patient samples.

[0061] Figure 23 shows the results of evaluating the anti-inflammatory efficacy of P001009v1 in an animal model of multiple sclerosis.

[0062] Figure 24 shows the results of evaluating the anti-inflammatory efficacy of P001009v1 in a contact dermatitis model.

[0063]

[0064] Detailed description of the invention and preferred embodiments

[0065] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. In general, the nomenclature used herein is well known and commonly used in the art.

[0066]

[0067] anti-CD200R1 antibody

[0068] The present invention, from one aspect,

[0069] A heavy chain CDR1 comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 8, SEQ ID NOs: 100 to 103, and SEQ ID NO: 158;

[0070] A heavy chain CDR2 comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 9 to 21, SEQ ID NOs: 104 to 109, and SEQ ID NO: 159;

[0071] A heavy chain CDR3 comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 22 to 35, SEQ ID NOs: 110 to 115, SEQ ID NOs: 160, SEQ ID NOs: 172 and 173;

[0072] A light chain CDR1 comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 36 to 47, SEQ ID NOs: 116 to 122, SEQ ID NOs: 161, SEQ ID NOs: 192, and SEQ ID NOs: 193;

[0073] A light chain CDR2 comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 48 to 58, SEQ ID NOs: 123 to 127, SEQ ID NO: 162, and SEQ ID NO: 194; and

[0074] Comprising a light chain CDR3 comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 59 to 70, SEQ ID NOs: 128 to 134, SEQ ID NOs: 163, SEQ ID NOs: 174 to 183, SEQ ID NOs: 195, and SEQ ID NOs: 196;

[0075] It relates to an antibody or antigen-binding fragment thereof that specifically binds to CD200R1.

[0076] As used herein, the term "antibody" refers to an anti-CD200R1 antibody that specifically binds to CD200R1. The scope of the present invention includes not only complete antibody forms that specifically bind to CD200R1, but also antigen-binding fragments of such antibody molecules.

[0077] A complete antibody is a structure having two full-length light chains and two full-length heavy chains, each light chain linked to a heavy chain by a disulfide bond.

[0078] As used herein, the term "heavy chain" refers to a full-length heavy chain and fragments thereof, which comprises a variable domain VH comprising an amino acid sequence having sufficient variable region sequence to confer specificity to an antigen, and three constant region domains CH1, CH2, and CH3. In addition, the term "light chain" as used herein refers to a full-length light chain and fragments thereof, which comprises a variable domain VL comprising an amino acid sequence having sufficient variable region sequence to confer specificity to an antigen, and a constant region domain CL.

[0079] The above whole antibodies include subtypes of IgA, IgD, IgE, IgM and IgG, and in particular, IgG includes IgG1, IgG2, IgG3 and IgG4. The heavy chain constant region has gamma (γ), mu (μ), alpha (α), delta (δ) and epsilon (ε) types, and has subclasses of gamma1 (γ1), gamma2 (γ2), gamma3 (γ3), gamma4 (γ4), alpha1 (α1) and alpha2 (α2). The light chain constant region has kappa (κ) and lambda (λ) types.

[0080] Antigen-binding fragments of antibodies, or antibody fragments, refer to fragments that possess antigen-binding function, and include Fab, F(ab'), F(ab')2, and Fv. Among antibody fragments, Fab has a structure with variable regions of the light and heavy chains, a constant region of the light chain, and the first constant region (CH1) of the heavy chain, and has one antigen-binding site. Fab' differs from Fab in that it has a hinge region containing one or more cysteine ​​residues at the C-terminus of the heavy chain CH1 domain. F(ab')2 is generated when the cysteine ​​residues in the hinge region of Fab' form a disulfide bond.

[0081] Fv is the smallest antibody fragment that contains only the heavy chain variable region and the light chain variable region. A two-chain Fv has a heavy chain variable region and a light chain variable region non-covalently linked, while a single-chain Fv (single-chain Fv, scFv) has a heavy chain variable region and a light chain variable region covalently linked, usually via a peptide linker, or directly linked at the C-terminus, so that it can form a dimer-like structure like a two-chain Fv. These antibody fragments can be produced using proteolytic enzymes (for example, restriction digestion of a complete antibody with papain yields Fab, and digestion with pepsin yields F(ab')2) or using genetic recombination technology.

[0082] An "Fv" fragment is an antibody fragment containing the complete antibody recognition and binding site. This region is a dimer composed of one heavy chain variable domain and one light chain variable domain.

[0083] The "Fab" fragment comprises the variable and constant domains of the light chain and the variable and first constant domain (CH1) of the heavy chain. An F(ab')2 antibody fragment typically comprises a pair of Fab' fragments covalently linked by cysteines in the hinge region at the C-terminus of the Fab' fragment.

[0084] A "single-chain Fv (scFv)" antibody fragment is a construct consisting of a single polypeptide chain comprising the VH and VL domains of an antibody. The scFv may additionally comprise a polypeptide linker between the VH and VL domains that allows it to form the desired structure for antigen binding.

[0085] In one embodiment, the antibodies of the present invention include, but are not limited to, monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, chimeric antibodies, scFvs, Fab fragments, F(ab')2 fragments, disulfide-linked Fvs (sdFvs) and anti-idiotypic (anti-Id) antibodies, or epitope-binding fragments of the foregoing antibodies.

[0086] The heavy chain constant region can be selected from any one of the gamma (γ), mu (μ), alpha (α), delta (δ), or epsilon (ε) isotypes. For example, the constant region is gamma 1 (IgG1), gamma 2 (IgG2), gamma 3 (IgG3), or gamma 4 (IgG4). The light chain constant region can be kappa or lambda type.

[0087] The term "monoclonal antibody" refers to antibodies obtained from a substantially homogeneous population of antibodies, i.e., antibodies that are identical except for possible naturally occurring mutations that may be present in trace amounts in individual antibodies within the population. Monoclonal antibodies are highly specific, being directed against a single antigenic site. In contrast to conventional (polyclonal) antibodies, which typically contain different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.

[0088] An "epitope" is a protein determinant to which an antibody can specifically bind. Epitopes typically consist of chemically active surface molecules, such as amino acids or sugar side chains, and typically have specific three-dimensional structural features as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished by the fact that binding to the former is lost in the presence of denaturing solvents, while binding to the latter is not.

[0089] The above "humanized" forms of non-human (e.g., mouse) antibodies are chimeric antibodies that contain minimal sequence derived from a non-human immunoglobulin. In most cases, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from the hypervariable region of the recipient antibody have been replaced with residues from the hypervariable region of a non-human species (donor antibody) that retains the desired specificity, affinity, and ability, such as mouse, rat, rabbit, or non-human primate.

[0090] The above "human antibody" means a molecule derived from human immunoglobulin, and the entire amino acid sequence constituting the antibody, including the complementarity determining region and structural region, is composed of human immunoglobulin.

[0091] "Chimeric" antibodies (immunoglobulins) in which a portion of the heavy and / or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies that exhibit the desired biological activity.

[0092] The "variable region" of an antibody used in the present invention refers to the light chain and heavy chain portions of an antibody molecule, including the amino acid sequences of the complementarity determining regions (CDRs; i.e., CDR1, CDR2, and CDR3) and the framework regions (FR). VH refers to the variable domain of the heavy chain. VL refers to the variable domain of the light chain.

[0093] "Complementary determining region (CDR)" refers to the amino acid residues in an antibody variable domain that are necessary for antigen binding. Each variable domain typically has three CDR regions, identified as CDR1, CDR2, and CDR3.

[0094] In the present invention, the antibody or antigen-binding fragment thereof may be characterized by comprising a heavy chain variable region selected from the group consisting of:

[0095] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 1, a heavy chain CDR2 of SEQ ID NO: 9, and a heavy chain CDR3 of SEQ ID NO: 22;

[0096] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 2, a heavy chain CDR2 of SEQ ID NO: 10, and a heavy chain CDR3 of SEQ ID NO: 23;

[0097] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 3, a heavy chain CDR2 of SEQ ID NO: 11, and a heavy chain CDR3 of SEQ ID NO: 24;

[0098] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 4, a heavy chain CDR2 of SEQ ID NO: 12, and a heavy chain CDR3 of SEQ ID NO: 25;

[0099] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 5, a heavy chain CDR2 of SEQ ID NO: 13, and a heavy chain CDR3 of SEQ ID NO: 26;

[0100] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 3, a heavy chain CDR2 of SEQ ID NO: 14, and a heavy chain CDR3 of SEQ ID NO: 27;

[0101] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 6, a heavy chain CDR2 of SEQ ID NO: 15, and a heavy chain CDR3 of SEQ ID NO: 28;

[0102] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 7, a heavy chain CDR2 of SEQ ID NO: 16, and a heavy chain CDR3 of SEQ ID NO: 29;

[0103] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 7, a heavy chain CDR2 of SEQ ID NO: 16, and a heavy chain CDR3 of SEQ ID NO: 30;

[0104] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 8, a heavy chain CDR2 of SEQ ID NO: 17, and a heavy chain CDR3 of SEQ ID NO: 31;

[0105] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 4, a heavy chain CDR2 of SEQ ID NO: 18, and a heavy chain CDR3 of SEQ ID NO: 32;

[0106] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 5, a heavy chain CDR2 of SEQ ID NO: 19, and a heavy chain CDR3 of SEQ ID NO: 33;

[0107] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 5, a heavy chain CDR2 of SEQ ID NO: 20, and a heavy chain CDR3 of SEQ ID NO: 34;

[0108] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 5, a heavy chain CDR2 of SEQ ID NO: 21, and a heavy chain CDR3 of SEQ ID NO: 35;

[0109] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 100, a heavy chain CDR2 of SEQ ID NO: 104, and a heavy chain CDR3 of SEQ ID NO: 110;

[0110] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 101, a heavy chain CDR2 of SEQ ID NO: 105, and a heavy chain CDR3 of SEQ ID NO: 111;

[0111] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 100, a heavy chain CDR2 of SEQ ID NO: 106, and a heavy chain CDR3 of SEQ ID NO: 112;

[0112] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 102, a heavy chain CDR2 of SEQ ID NO: 107, and a heavy chain CDR3 of SEQ ID NO: 113;

[0113] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 100, a heavy chain CDR2 of SEQ ID NO: 106, and a heavy chain CDR3 of SEQ ID NO: 110;

[0114] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 103, a heavy chain CDR2 of SEQ ID NO: 108, and a heavy chain CDR3 of SEQ ID NO: 114;

[0115] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 100, a heavy chain CDR2 of SEQ ID NO: 109, and a heavy chain CDR3 of SEQ ID NO: 115;

[0116] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 158, a heavy chain CDR2 of SEQ ID NO: 159, and a heavy chain CDR3 of SEQ ID NO: 160;

[0117] - a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 158, a heavy chain CDR2 of SEQ ID NO: 159, and a heavy chain CDR3 of SEQ ID NO: 172; and

[0118] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 158, a heavy chain CDR2 of SEQ ID NO: 159, and a heavy chain CDR3 of SEQ ID NO: 173.

[0119] In the present invention, the antibody or antigen-binding fragment thereof may be characterized by comprising any one light chain variable region selected from the group consisting of:

[0120] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 36, a light chain CDR2 of SEQ ID NO: 48, and a light chain CDR3 of SEQ ID NO: 59;

[0121] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 37, a light chain CDR2 of SEQ ID NO: 49, and a light chain CDR3 of SEQ ID NO: 60;

[0122] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 38, a light chain CDR2 of SEQ ID NO: 50, and a light chain CDR3 of SEQ ID NO: 61;

[0123] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 37, a light chain CDR2 of SEQ ID NO: 51, and a light chain CDR3 of SEQ ID NO: 62;

[0124] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 39, a light chain CDR2 of SEQ ID NO: 51, and a light chain CDR3 of SEQ ID NO: 62;

[0125] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 40, a light chain CDR2 of SEQ ID NO: 52, and a light chain CDR3 of SEQ ID NO: 63;

[0126] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 41, a light chain CDR2 of SEQ ID NO: 53, and a light chain CDR3 of SEQ ID NO: 64;

[0127] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 42, a light chain CDR2 of SEQ ID NO: 53, and a light chain CDR3 of SEQ ID NO: 65;

[0128] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 43, a light chain CDR2 of SEQ ID NO: 54, and a light chain CDR3 of SEQ ID NO: 66;

[0129] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 44, a light chain CDR2 of SEQ ID NO: 55, and a light chain CDR3 of SEQ ID NO: 65;

[0130] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 45, a light chain CDR2 of SEQ ID NO: 56, and a light chain CDR3 of SEQ ID NO: 67;

[0131] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 46, a light chain CDR2 of SEQ ID NO: 53, and a light chain CDR3 of SEQ ID NO: 68;

[0132] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 39, a light chain CDR2 of SEQ ID NO: 57, and a light chain CDR3 of SEQ ID NO: 69;

[0133] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 47, a light chain CDR2 of SEQ ID NO: 58, and a light chain CDR3 of SEQ ID NO: 70;

[0134] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 116, a light chain CDR2 of SEQ ID NO: 123, and a light chain CDR3 of SEQ ID NO: 128;

[0135] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 117, a light chain CDR2 of SEQ ID NO: 124, and a light chain CDR3 of SEQ ID NO: 129;

[0136] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 118, a light chain CDR2 of SEQ ID NO: 125, and a light chain CDR3 of SEQ ID NO: 130;

[0137] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 119, a light chain CDR2 of SEQ ID NO: 124, and a light chain CDR3 of SEQ ID NO: 131;

[0138] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 120, a light chain CDR2 of SEQ ID NO: 125, and a light chain CDR3 of SEQ ID NO: 132;

[0139] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 121, a light chain CDR2 of SEQ ID NO: 126, and a light chain CDR3 of SEQ ID NO: 133;

[0140] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 122, a light chain CDR2 of SEQ ID NO: 127, and a light chain CDR3 of SEQ ID NO: 134;

[0141] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 163;

[0142] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 174;

[0143] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 175;

[0144] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 176;

[0145] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 177;

[0146] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 178;

[0147] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 179;

[0148] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 180;

[0149] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 181;

[0150] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 182;

[0151] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 183;

[0152] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 43, a light chain CDR2 of SEQ ID NO: 194, and a light chain CDR3 of SEQ ID NO: 195;

[0153] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 43, a light chain CDR2 of SEQ ID NO: 194, and a light chain CDR3 of SEQ ID NO: 196;

[0154] - a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 192, a light chain CDR2 of SEQ ID NO: 54, and a light chain CDR3 of SEQ ID NO: 66; and

[0155] - A light chain variable region comprising a light chain CDR1 of SEQ ID NO: 193, a light chain CDR2 of SEQ ID NO: 54, and a light chain CDR3 of SEQ ID NO: 66.

[0156] In the present invention, the antibody or antigen-binding fragment thereof may be characterized by comprising one of the following heavy chain variable regions and light chain variable regions:

[0157] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 1, a heavy chain CDR2 of SEQ ID NO: 9, and a heavy chain CDR3 of SEQ ID NO: 22; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 36, a light chain CDR2 of SEQ ID NO: 48, and a light chain CDR3 of SEQ ID NO: 59;

[0158] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 2, a heavy chain CDR2 of SEQ ID NO: 10, and a heavy chain CDR3 of SEQ ID NO: 23; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 37, a light chain CDR2 of SEQ ID NO: 49, and a light chain CDR3 of SEQ ID NO: 60;

[0159] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 3, a heavy chain CDR2 of SEQ ID NO: 11, and a heavy chain CDR3 of SEQ ID NO: 24; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 38, a light chain CDR2 of SEQ ID NO: 50, and a light chain CDR3 of SEQ ID NO: 61;

[0160] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 4, a heavy chain CDR2 of SEQ ID NO: 12, and a heavy chain CDR3 of SEQ ID NO: 25; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 37, a light chain CDR2 of SEQ ID NO: 51, and a light chain CDR3 of SEQ ID NO: 62;

[0161] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 5, a heavy chain CDR2 of SEQ ID NO: 13, and a heavy chain CDR3 of SEQ ID NO: 26; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 39, a light chain CDR2 of SEQ ID NO: 51, and a light chain CDR3 of SEQ ID NO: 62;

[0162] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 3, a heavy chain CDR2 of SEQ ID NO: 14, and a heavy chain CDR3 of SEQ ID NO: 27; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 40, a light chain CDR2 of SEQ ID NO: 52, and a light chain CDR3 of SEQ ID NO: 63;

[0163] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 6, a heavy chain CDR2 of SEQ ID NO: 15, and a heavy chain CDR3 of SEQ ID NO: 28; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 41, a light chain CDR2 of SEQ ID NO: 53, and a light chain CDR3 of SEQ ID NO: 64;

[0164] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 7, a heavy chain CDR2 of SEQ ID NO: 16, and a heavy chain CDR3 of SEQ ID NO: 29; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 42, a light chain CDR2 of SEQ ID NO: 53, and a light chain CDR3 of SEQ ID NO: 65;

[0165] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 7, a heavy chain CDR2 of SEQ ID NO: 16, and a heavy chain CDR3 of SEQ ID NO: 30; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 43, a light chain CDR2 of SEQ ID NO: 54, and a light chain CDR3 of SEQ ID NO: 66;

[0166] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 8, a heavy chain CDR2 of SEQ ID NO: 17, and a heavy chain CDR3 of SEQ ID NO: 31; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 44, a light chain CDR2 of SEQ ID NO: 55, and a light chain CDR3 of SEQ ID NO: 65;

[0167] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 4, a heavy chain CDR2 of SEQ ID NO: 18, and a heavy chain CDR3 of SEQ ID NO: 32; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 45, a light chain CDR2 of SEQ ID NO: 56, and a light chain CDR3 of SEQ ID NO: 67;

[0168] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 5, a heavy chain CDR2 of SEQ ID NO: 19, and a heavy chain CDR3 of SEQ ID NO: 33; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 46, a light chain CDR2 of SEQ ID NO: 53, and a light chain CDR3 of SEQ ID NO: 68;

[0169] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 5, a heavy chain CDR2 of SEQ ID NO: 20, and a heavy chain CDR3 of SEQ ID NO: 34; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 39, a light chain CDR2 of SEQ ID NO: 57, and a light chain CDR3 of SEQ ID NO: 69;

[0170] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 5, a heavy chain CDR2 of SEQ ID NO: 21, and a heavy chain CDR3 of SEQ ID NO: 35; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 47, a light chain CDR2 of SEQ ID NO: 58, and a light chain CDR3 of SEQ ID NO: 70;

[0171] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 100, a heavy chain CDR2 of SEQ ID NO: 104, and a heavy chain CDR3 of SEQ ID NO: 110; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 116, a light chain CDR2 of SEQ ID NO: 123, and a light chain CDR3 of SEQ ID NO: 128;

[0172] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 101, a heavy chain CDR2 of SEQ ID NO: 105, and a heavy chain CDR3 of SEQ ID NO: 111; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 117, a light chain CDR2 of SEQ ID NO: 124, and a light chain CDR3 of SEQ ID NO: 129;

[0173] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 100, a heavy chain CDR2 of SEQ ID NO: 106, and a heavy chain CDR3 of SEQ ID NO: 112; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 118, a light chain CDR2 of SEQ ID NO: 125, and a light chain CDR3 of SEQ ID NO: 130;

[0174] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 102, a heavy chain CDR2 of SEQ ID NO: 107, and a heavy chain CDR3 of SEQ ID NO: 113; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 119, a light chain CDR2 of SEQ ID NO: 124, and a light chain CDR3 of SEQ ID NO: 131;

[0175] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 100, a heavy chain CDR2 of SEQ ID NO: 106, and a heavy chain CDR3 of SEQ ID NO: 110; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 120, a light chain CDR2 of SEQ ID NO: 125, and a light chain CDR3 of SEQ ID NO: 132;

[0176] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 103, a heavy chain CDR2 of SEQ ID NO: 108, and a heavy chain CDR3 of SEQ ID NO: 114; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 121, a light chain CDR2 of SEQ ID NO: 126, and a light chain CDR3 of SEQ ID NO: 133;

[0177] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 100, a heavy chain CDR2 of SEQ ID NO: 109, and a heavy chain CDR3 of SEQ ID NO: 115; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 122, a light chain CDR2 of SEQ ID NO: 127, and a light chain CDR3 of SEQ ID NO: 134;

[0178] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 158, a heavy chain CDR2 of SEQ ID NO: 159, and a heavy chain CDR3 of SEQ ID NO: 160; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 163;

[0179] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 158, a heavy chain CDR2 of SEQ ID NO: 159, and a heavy chain CDR3 of SEQ ID NO: 172; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 163;

[0180] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 158, a heavy chain CDR2 of SEQ ID NO: 159, and a heavy chain CDR3 of SEQ ID NO: 173; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 163;

[0181] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 158, a heavy chain CDR2 of SEQ ID NO: 159, and a heavy chain CDR3 of SEQ ID NO: 160; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 174;

[0182] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 158, a heavy chain CDR2 of SEQ ID NO: 159, and a heavy chain CDR3 of SEQ ID NO: 160; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 175;

[0183] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 158, a heavy chain CDR2 of SEQ ID NO: 159, and a heavy chain CDR3 of SEQ ID NO: 160; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 176;

[0184] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 158, a heavy chain CDR2 of SEQ ID NO: 159, and a heavy chain CDR3 of SEQ ID NO: 160; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 177;

[0185] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 158, a heavy chain CDR2 of SEQ ID NO: 159, and a heavy chain CDR3 of SEQ ID NO: 160; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 178;

[0186] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 158, a heavy chain CDR2 of SEQ ID NO: 159, and a heavy chain CDR3 of SEQ ID NO: 160; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 179;

[0187] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 158, a heavy chain CDR2 of SEQ ID NO: 159, and a heavy chain CDR3 of SEQ ID NO: 160; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 180;

[0188] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 158, a heavy chain CDR2 of SEQ ID NO: 159, and a heavy chain CDR3 of SEQ ID NO: 173; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 174;

[0189] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 158, a heavy chain CDR2 of SEQ ID NO: 159, and a heavy chain CDR3 of SEQ ID NO: 173; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 178;

[0190] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 158, a heavy chain CDR2 of SEQ ID NO: 159, and a heavy chain CDR3 of SEQ ID NO: 160; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 181;

[0191] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 158, a heavy chain CDR2 of SEQ ID NO: 159, and a heavy chain CDR3 of SEQ ID NO: 173; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 182;

[0192] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 158, a heavy chain CDR2 of SEQ ID NO: 159, and a heavy chain CDR3 of SEQ ID NO: 173; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 161, a light chain CDR2 of SEQ ID NO: 162, and a light chain CDR3 of SEQ ID NO: 183;

[0193] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 7, a heavy chain CDR2 of SEQ ID NO: 16, and a heavy chain CDR3 of SEQ ID NO: 30; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 43, a light chain CDR2 of SEQ ID NO: 194, and a light chain CDR3 of SEQ ID NO: 195;

[0194] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 7, a heavy chain CDR2 of SEQ ID NO: 16, and a heavy chain CDR3 of SEQ ID NO: 30; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 43, a light chain CDR2 of SEQ ID NO: 194, and a light chain CDR3 of SEQ ID NO: 196;

[0195] - a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 7, a heavy chain CDR2 of SEQ ID NO: 16, and a heavy chain CDR3 of SEQ ID NO: 30; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 192, a light chain CDR2 of SEQ ID NO: 54, and a light chain CDR3 of SEQ ID NO: 66; and

[0196] - A heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 7, a heavy chain CDR2 of SEQ ID NO: 16, and a heavy chain CDR3 of SEQ ID NO: 30; and a light chain variable region comprising a light chain CDR1 of SEQ ID NO: 193, a light chain CDR2 of SEQ ID NO: 54, and a light chain CDR3 of SEQ ID NO: 66.

[0197] "Framework regions (FR)" are variable domain residues other than CDR residues. Each variable domain typically has four FRs: FR1, FR2, FR3, and FR4.

[0198] The binding affinity of anti-CD200R1 antibody to CD200R1 is 10 -5 M to 10 -13 is within the M range. For example, the binding affinity of anti-CD200R1 antibody to CD200R1 is 10 -6 M to 10 -13 M, 10 -7 M to 10 -13 M, 10-8 M to 10 -13 M, 10 -9 M to 10 -13 M, 10 -5 M to 10 -11 M, 10 -6 M to 10 -11 M, 10 -7 M to 10 -11 M, 10 -8 M to 10 -11 M, 10 -9 M to 10 -11 M, 10 -10 M to 10 -11 M, 10 -5 M to 10 -10 M, 10 -6 M to 10 -10 M, 10 -7 M to 10 -10 M, 10 -8 M to 10 -10 M, 10 -9 M to 10 -10 M, 10 -5 M to 10 -9 M, 10 -6 M to 10 -9 M, 10 -7 M to 10 -9 M, 10 -8 M to 10 -9 M, 10 -5 M to 10 -8 M, 10 -6 M to 10 -8 M, 10 -7 M to 10 -8 M, 10 -5 M to 10 -7 M, 10 -6 M to 10 -7 M or 10 -5 M to 10 -6 It's M.

[0199] In the present invention, the antibody or antigen-binding fragment thereof that binds to CD200R1 may include a heavy chain variable region comprising one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 71 to 85, SEQ ID NOs: 135 to 141, SEQ ID NOs: 149 to 153, SEQ ID NO: 184, and SEQ ID NO: 185.

[0200] In the present invention, the antibody or antigen-binding fragment thereof that binds to CD200R1 may include a light chain variable region comprising one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 86 to 99, SEQ ID NOs: 142 to 148, SEQ ID NOs: 154 to 157, and SEQ ID NOs: 186 to 191, and SEQ ID NOs: 197 to 200.

[0201] In specific embodiments of the present invention, the following may be included:

[0202] - A heavy chain variable region of sequence number 71 and a light chain variable region of sequence number 86;

[0203] - A heavy chain variable region of sequence number 72 and a light chain variable region of sequence number 87;

[0204] - A heavy chain variable region of sequence number 73 and a light chain variable region of sequence number 88;

[0205] - A heavy chain variable region of sequence number 74 and a light chain variable region of sequence number 89;

[0206] - A heavy chain variable region of sequence number 75 and a light chain variable region of sequence number 90;

[0207] - A heavy chain variable region of sequence number 76 and a light chain variable region of sequence number 91;

[0208] - A heavy chain variable region of sequence number 77 and a light chain variable region of sequence number 92;

[0209] - A heavy chain variable region of SEQ ID NO: 78 and a light chain variable region of SEQ ID NO: 93;

[0210] - A heavy chain variable region of sequence number 79 and a light chain variable region of sequence number 94;

[0211] - A heavy chain variable region of sequence number 80 and a light chain variable region of sequence number 95;

[0212] - A heavy chain variable region of sequence number 81 and a light chain variable region of sequence number 96;

[0213] - A heavy chain variable region of sequence number 82 and a light chain variable region of sequence number 97;

[0214] - A heavy chain variable region of sequence number 83 and a light chain variable region of sequence number 98;

[0215] - A heavy chain variable region of SEQ ID NO: 84 and a light chain variable region of SEQ ID NO: 94;

[0216] - A heavy chain variable region of sequence number 85 and a light chain variable region of sequence number 99;

[0217] - A heavy chain variable region of sequence number 135 and a light chain variable region of sequence number 142;

[0218] - A heavy chain variable region of sequence number 136 and a light chain variable region of sequence number 143;

[0219] - A heavy chain variable region of sequence number 137 and a light chain variable region of sequence number 144;

[0220] - A heavy chain variable region of sequence number 138 and a light chain variable region of sequence number 145;

[0221] - A heavy chain variable region of sequence number 139 and a light chain variable region of sequence number 146;

[0222] - A heavy chain variable region of sequence number 140 and a light chain variable region of sequence number 147;

[0223] - A heavy chain variable region of SEQ ID NO: 141 and a light chain variable region of SEQ ID NO: 148;

[0224] - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 155;

[0225] - A heavy chain variable region of sequence number 151 and a light chain variable region of sequence number 155;

[0226] - A heavy chain variable region of SEQ ID NO: 152 and a light chain variable region of SEQ ID NO: 157;

[0227] - A heavy chain variable region of SEQ ID NO: 153 and a light chain variable region of SEQ ID NO: 157;

[0228] - A heavy chain variable region of sequence number 151 and a light chain variable region of sequence number 157;

[0229] - A heavy chain variable region of sequence number 152 and a light chain variable region of sequence number 155;

[0230] - A heavy chain variable region of SEQ ID NO: 184 and a light chain variable region of SEQ ID NO: 155;

[0231] - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 186;

[0232] - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 187;

[0233] - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 188;

[0234] - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 189;

[0235] - A heavy chain variable region of sequence number 185 and a light chain variable region of sequence number 155;

[0236] - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 190;

[0237] - A heavy chain variable region of sequence number 185 and a light chain variable region of sequence number 186;

[0238] - A heavy chain variable region of sequence number 185 and a light chain variable region of sequence number 187;

[0239] - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 191;

[0240] - A heavy chain variable region of sequence number 185 and a light chain variable region of sequence number 190;

[0241] - A heavy chain variable region of sequence number 185 and a light chain variable region of sequence number 191;

[0242] - A heavy chain variable region of SEQ ID NO: 79 and a light chain variable region of SEQ ID NO: 197;

[0243] - A heavy chain variable region of SEQ ID NO: 79 and a light chain variable region of SEQ ID NO: 198;

[0244] - a heavy chain variable region of SEQ ID NO: 79 and a light chain variable region of SEQ ID NO: 199; or

[0245] - A heavy chain variable region of sequence number 79 and a light chain variable region of sequence number 200.

[0246]

[0247] scFv

[0248] An scFv is an antibody fragment, consisting of a single polypeptide chain containing the VH and VL domains of an antibody. The scFv may additionally contain a polypeptide linker between the VH and VL domains, enabling it to form the desired structure for antigen binding.

[0249] In one embodiment, in a single-chain Fv (scFv) comprising the VH and VL domains of an antibody, the VH and VL domains can be linked via a linker. A heavy chain variable region comprising one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 71 to 85, SEQ ID NOs: 135 to 141, SEQ ID NOs: 149 to 153, SEQ ID NOs: 184, and SEQ ID NOs: 185 can be linked via a linker to a light chain variable region comprising one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 86 to 99, SEQ ID NOs: 142 to 148, SEQ ID NOs: 154 to 157, SEQ ID NOs: 186 to 191, and SEQ ID NOs: 197 to 200.

[0250] In specific embodiments of the present invention, the following may be included:

[0251] - A heavy chain variable region of sequence number 71 and a light chain variable region of sequence number 86;

[0252] - A heavy chain variable region of sequence number 72 and a light chain variable region of sequence number 87;

[0253] - A heavy chain variable region of sequence number 73 and a light chain variable region of sequence number 88;

[0254] - A heavy chain variable region of sequence number 74 and a light chain variable region of sequence number 89;

[0255] - A heavy chain variable region of sequence number 75 and a light chain variable region of sequence number 90;

[0256] - A heavy chain variable region of sequence number 76 and a light chain variable region of sequence number 91;

[0257] - A heavy chain variable region of sequence number 77 and a light chain variable region of sequence number 92;

[0258] - A heavy chain variable region of SEQ ID NO: 78 and a light chain variable region of SEQ ID NO: 93;

[0259] - A heavy chain variable region of sequence number 79 and a light chain variable region of sequence number 94;

[0260] - A heavy chain variable region of sequence number 80 and a light chain variable region of sequence number 95;

[0261] - A heavy chain variable region of sequence number 81 and a light chain variable region of sequence number 96;

[0262] - A heavy chain variable region of sequence number 82 and a light chain variable region of sequence number 97;

[0263] - A heavy chain variable region of sequence number 83 and a light chain variable region of sequence number 98;

[0264] - A heavy chain variable region of SEQ ID NO: 84 and a light chain variable region of SEQ ID NO: 94;

[0265] - A heavy chain variable region of sequence number 85 and a light chain variable region of sequence number 99;

[0266] - A heavy chain variable region of sequence number 135 and a light chain variable region of sequence number 142;

[0267] - A heavy chain variable region of sequence number 136 and a light chain variable region of sequence number 143;

[0268] - A heavy chain variable region of sequence number 137 and a light chain variable region of sequence number 144;

[0269] - A heavy chain variable region of sequence number 138 and a light chain variable region of sequence number 145;

[0270] - A heavy chain variable region of sequence number 139 and a light chain variable region of sequence number 146;

[0271] - A heavy chain variable region of sequence number 140 and a light chain variable region of sequence number 147;

[0272] - A heavy chain variable region of SEQ ID NO: 141 and a light chain variable region of SEQ ID NO: 148;

[0273] - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 155;

[0274] - A heavy chain variable region of sequence number 151 and a light chain variable region of sequence number 155;

[0275] - A heavy chain variable region of SEQ ID NO: 152 and a light chain variable region of SEQ ID NO: 157;

[0276] - A heavy chain variable region of SEQ ID NO: 153 and a light chain variable region of SEQ ID NO: 157;

[0277] - A heavy chain variable region of sequence number 151 and a light chain variable region of sequence number 157;

[0278] - A heavy chain variable region of sequence number 152 and a light chain variable region of sequence number 155;

[0279] - A heavy chain variable region of SEQ ID NO: 184 and a light chain variable region of SEQ ID NO: 155;

[0280] - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 186;

[0281] - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 187;

[0282] - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 188;

[0283] - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 189;

[0284] - A heavy chain variable region of sequence number 185 and a light chain variable region of sequence number 155;

[0285] - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 190;

[0286] - A heavy chain variable region of sequence number 185 and a light chain variable region of sequence number 186;

[0287] - A heavy chain variable region of sequence number 185 and a light chain variable region of sequence number 187;

[0288] - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 191;

[0289] - A heavy chain variable region of sequence number 185 and a light chain variable region of sequence number 190;

[0290] - A heavy chain variable region of sequence number 185 and a light chain variable region of sequence number 191;

[0291] - A heavy chain variable region of SEQ ID NO: 79 and a light chain variable region of SEQ ID NO: 197;

[0292] - A heavy chain variable region of SEQ ID NO: 79 and a light chain variable region of SEQ ID NO: 198;

[0293] - a heavy chain variable region of SEQ ID NO: 79 and a light chain variable region of SEQ ID NO: 199; or

[0294] - A heavy chain variable region of sequence number 79 and a light chain variable region of sequence number 200.

[0295] In another embodiment, the scFv may comprise an amino acid sequence of SEQ ID NOs: 164 to 171.

[0296] The linker may be a peptide linker and may have a length of about 10-25 aa. For example, it may include, but is not limited to, hydrophilic amino acids such as glycine and / or serine.

[0297] Specifically, the linker may be, for example, (GS) n , (GGS) n , (GSGGS) n or (G n S) m (n, m are 1 to 10 respectively) may be included, but the linker may be, for example, (G n S) m (n, m may be 1 to 10, respectively). Specifically, the linker may include GGGGS, for example, GGGGSGGGGSGGGGS of SEQ ID NO: 200 repeated three times.

[0298] "Phage display" is a technique for displaying variant polypeptides as fusion proteins with at least a portion of the coat protein on the surface of phage, such as filamentous phage particles. The utility of phage display lies in its ability to rapidly and efficiently sort sequences that bind with high affinity to a target antigen from a large library of randomized protein variants. Displaying peptide and protein libraries on phage has been used to screen millions of polypeptides for polypeptides with specific binding properties.

[0299] Phage display technology has provided a powerful tool for generating and screening novel proteins that bind to specific ligands (e.g., antigens). Using phage display technology, large libraries of protein variants can be generated and sequences that bind with high affinity to a target antigen can be rapidly sorted. Nucleic acids encoding variant polypeptides were fused to nucleic acid sequences encoding viral envelope proteins, such as gene III protein or gene VIII protein. A monovalent phage display system was developed in which a nucleic acid sequence encoding a protein or polypeptide was fused to a nucleic acid sequence encoding a portion of gene III protein. In this monovalent phage display system, the gene fusion is expressed at low levels, while the wild-type gene III protein is also expressed, maintaining particle infectivity.

[0300] Demonstrating the expression of peptides on the surface of filamentous phage and the expression of functional antibody fragments in the periplasm of E. coli is crucial for developing antibody phage display libraries. Libraries of antibodies or antigen-binding polypeptides have been generated in a number of ways, including by modifying single genes by inserting random DNA sequences or by cloning related gene families. Libraries can be screened for the expression of antibodies or antigen-binding proteins with desired characteristics.

[0301] Phage display technology offers several advantages over conventional hybridoma and recombinant methods for producing antibodies with desired characteristics. This technology allows for the rapid generation of large antibody libraries with diverse sequences without the use of animals. Hybridoma production or humanized antibody production can require several months of production time. Furthermore, because no immunization is required, phage antibody libraries can generate antibodies even against antigens that are toxic or have low antigenicity. Phage antibody libraries can also be used to generate and identify novel therapeutic antibodies.

[0302] Phage display libraries can be used to generate human antibodies from immunized, non-immunized, germline, or naive B cell Ig repertoires. Various lymphoid tissues can be used to generate naive or non-immunized antigen-binding libraries.

[0303] Techniques for identifying and isolating high-affinity antibodies from phage display libraries are crucial for isolating novel therapeutic antibodies. Isolation of high-affinity antibodies from a library can depend on library size, production efficiency in bacterial cells, and library diversity. Library size is reduced by inefficient production due to improper folding of antibodies or antigen-binding proteins and the presence of stop codons. Expression in bacterial cells can be inhibited if the antibody or antigen-binding domain is not properly folded. Expression can be improved by alternating mutations of residues at the variable / constant interface or in selected CDR residues. The sequence of the framework region is a key factor in ensuring proper folding when generating antibody phage libraries in bacterial cells.

[0304] In high-affinity antibody isolation, it is crucial to generate diverse libraries of antibodies or antigen-binding proteins. The CDR3 region has been shown to be frequently involved in antigen binding. Because the CDR3 region on the heavy chain is highly diverse in size, sequence, and structural conformation, it can be utilized to generate diverse libraries.

[0305] Additionally, diversity can be generated by randomizing the CDR regions of the variable heavy and light chains using all 20 amino acids at each position. Using all 20 amino acids can generate highly diverse variant antibody sequences and increase the chances of identifying novel antibodies.

[0306] The antibody or antibody fragment of the present invention may include not only the sequence of the anti-CD200R1 antibody of the present invention described herein, but also biological equivalents thereof, as long as it can specifically recognize CD200R1. For example, additional changes may be made to the amino acid sequence of the antibody to further improve the binding affinity and / or other biological properties of the antibody. Such modifications include, for example, deletions, insertions, and / or substitutions of amino acid sequence residues of the antibody. Such amino acid mutations are made based on the relative similarity of the amino acid side chain substituents, such as hydrophobicity, hydrophilicity, charge, size, etc. Analysis of the size, shape, and type of amino acid side chain substituents reveals that arginine, lysine, and histidine are all positively charged residues; alanine, glycine, and serine have similar sizes; and phenylalanine, tryptophan, and tyrosine have similar shapes. Therefore, based on these considerations, arginine, lysine, and histidine; Alanine, glycine and serine; and phenylalanine, tryptophan and tyrosine are biologically functional equivalents.

[0307] Considering the mutations having the above-described biological equivalent activity, the antibody of the present invention or the nucleic acid molecule encoding the same is interpreted to also include a sequence showing substantial identity with the sequence described in the SEQ ID NO. The substantial identity means a sequence showing at least 90% homology, most preferably at least 95% homology, 96% or more, 97% or more, 98% or more, or 99% or more homology when the sequence of the present invention is aligned with any other sequence to the greatest extent possible and the aligned sequence is analyzed using an algorithm commonly used in the art. Alignment methods for sequence comparison are known in the art. The NCBI Basic Local Alignment Search Tool (BLAST) is accessible from NBCI, etc., and can be used in conjunction with sequence analysis programs such as blastp, blasm, blastx, tblastn, and tblastx on the Internet. BLAST is accessible at www.ncbi.nlm.nih.gov / BLAST / . How to compare sequence homology using this program can be found at www.ncbi.nlm.nih.gov / BLAST / blast_ help.html.

[0308] Based on this, the antibody or antigen-binding fragment thereof of the present invention may have 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more homology to the specified sequences or the entirety of the sequences described in the specification. Such homology may be determined by sequence comparison and / or alignment using methods known in the art. For example, the percent sequence homology of the nucleic acids or proteins of the present invention may be determined using sequence comparison algorithms (i.e., BLAST or BLAST 2.0), manual alignment, or visual inspection.

[0309] From another perspective, the present invention relates to a nucleic acid encoding the antibody or antigen-binding fragment thereof. The nucleic acid encoding the antibody or antigen-binding fragment thereof of the present invention can be isolated to recombinantly produce the antibody or antigen-binding fragment thereof.

[0310] The term "nucleic acid" encompasses DNA (gDNA and cDNA) and RNA molecules. Nucleotides, the basic structural units of nucleic acids, include not only natural nucleotides but also analogues with modified sugar or base moieties. The sequence of the nucleic acid encoding the heavy and light chain variable regions of the present invention may be modified. Such modifications include additions, deletions, or non-conservative or conservative substitutions of nucleotides.

[0311] The DNA encoding the antibody can be readily isolated or synthesized using conventional molecular biological techniques (e.g., by using an oligonucleotide probe that can specifically bind to the DNA encoding the antibody and its heavy and light chains), and the nucleic acid can be isolated and further cloned (DNA amplification) or expressed by inserting it into a replicable vector. Based on this, the present invention relates to a recombinant expression vector comprising the nucleic acid from another aspect.

[0312] As used herein, the term "vector" refers to a means for expressing a target gene in a host cell, and includes viral vectors such as plasmid vectors, cosmid vectors, bacteriophage vectors, adenovirus vectors, retrovirus vectors, and adeno-associated virus vectors. Components of a vector typically include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more antibiotic resistance marker genes, an enhancer element, a promoter, and a transcription termination sequence. A nucleic acid encoding an antibody is operably linked to the promoter and the transcription termination sequence, etc.

[0313] "Operably linked" means a functional association between a nucleic acid expression regulatory sequence (e.g., a promoter, a signal sequence, or an array of transcription factor binding sites) and another nucleic acid sequence, whereby the regulatory sequence regulates transcription and / or translation of the other nucleic acid sequence.

[0314] In the case of a prokaryotic cell as a host, it is common to include a strong promoter that can drive transcription (e.g., tac promoter, lac promoter, lacUV5 promoter, lpp promoter, pLλ promoter, pRλ promoter, rac5 promoter, amp promoter, recA promoter, SP6 promoter, trp promoter, and T7 promoter), a ribosome binding site for translation initiation, and a transcription / translation termination sequence. In addition, for example, when a eukaryotic cell is used as a host, promoters derived from the genome of mammalian cells (e.g., metallothionine promoter, β-actin promoter, human hemoglobin promoter, and human muscle creatine promoter) or promoters derived from mammalian viruses (e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus (CMV) promoter, tk promoter of HSV, mouse mammary tumor virus (MMTV) promoter, LTR promoter of HIV, promoter of Moloney virus, promoter of Epstein-Barr virus (EBV), and promoter of Rous sarcoma virus (RSV)) can be used, and generally have a polyadenylation sequence as a transcription termination sequence.

[0315] In some cases, the vector may be fused with other sequences to facilitate purification of the antibody expressed therefrom. Sequences to be fused include, for example, glutathione S-transferase (Pharmacia, USA), maltose binding protein (NEB, USA), FLAG (IBI, USA), and 6x His (hexahistidine; Quiagen, USA).

[0316] The above vector contains antibiotic resistance genes commonly used in the art as selectable markers, for example, resistance genes for ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin and tetracycline.

[0317] In another aspect, the present invention relates to a host cell transfected with the recombinant expression vector. The host cell used to produce the antibody of the present invention may be a prokaryotic cell, yeast cell, or higher eukaryotic cell, but is not limited thereto.

[0318] Prokaryotic host cells can be used, such as strains of the genus Bacillus, such as Escherichia coli, Bacillus subtilus and Bacillus thuringiensis, Streptomyces, Pseudomonas (e.g., Pseudomonas putida), Proteus mirabilis and Staphylococcus (e.g., Staphylococcus carnosus).

[0319] However, animal cells are of greatest interest, and examples of useful host cell lines include, but are not limited to, COS-7, BHK, CHO, CHOK1, DXB-11, DG-44, CHO / -DHFR, CV1, COS-7, HEK293, BHK, TM4, VERO, HELA, MDCK, BRL 3A, W138, Hep G2, SK-Hep, MMT, TRI, MRC 5, FS4, 3T3, RIN, A549, PC12, K562, PER.C6, SP2 / 0, NS-0, U20S, or HT1080.

[0320] In another aspect, the present invention relates to a method for producing an antibody or an antigen-binding fragment thereof that specifically binds to CD200R1, comprising the steps of culturing the host cell to produce an antibody; and isolating and purifying the produced antibody.

[0321] The host cells described above can be cultured in various media. Any commercially available medium can be used as a culture medium. Any other essential supplements known to those skilled in the art may be included at appropriate concentrations. Culture conditions, such as temperature and pH, are already used with host cells selected for expression and will be readily apparent to those skilled in the art.

[0322] The antibody or antigen-binding fragment thereof can be recovered by removing impurities, for example, by centrifugation or ultrafiltration, and the resultant product can be purified, for example, by using affinity chromatography. Additional purification techniques, for example, anion or cation exchange chromatography, hydrophobic interaction chromatography, hydroxylapatite chromatography, etc., can be used.

[0323]

[0324] bispecific or multispecific antibodies

[0325] In another aspect, the present invention relates to a bispecific or multispecific antibody comprising the antibody or an antigen-binding fragment thereof.

[0326] A bispecific antibody refers to an antibody that has binding ability or antagonism to more than one target, and refers to an antibody in which antibodies with binding ability or antagonism to two different targets are combined, or an antibody in which an antibody with binding ability to one target and a substance with antagonism to another target are combined.

[0327] A multispecific antibody is an antibody that has binding specificities for at least three different antigens. A multispecific antibody may include an antibody that targets more than three targets, such as a trispecific antibody, a tetraspecific antibody, or an antibody that targets more than one target.

[0328] Antibodies belonging to bispecific or multispecific antibodies can be classified into scFv-based antibodies, Fab-based antibodies, and IgG-based antibodies. Bispecific or multispecific antibodies can be more effective than cases where two or more signals are simultaneously inhibited or amplified, and compared to cases where each signal is treated with a separate signal inhibitor, lower dosages are possible, and two or more signals can be inhibited or amplified in the same time and space.

[0329] Methods for producing bispecific or multispecific antibodies are widely known. Traditionally, recombinant production of bispecific antibodies relies on the co-expression of two or more immunoglobulin heavy / light chain pairs, where the two or more heavy chains possess different specificities.

[0330] In the case of bispecific or multispecific antibodies based on scFv, the VL and VH of different scFvs can be combined with each other to produce a hybrid scFv in a heterodimeric form to produce a diabody, different scFvs can be linked to each other to produce a tendem ScFv, the CH1 and CL of Fab can be expressed at the ends of each scFv to produce a heterodimeric miniantibody, and some amino acids of the CH3 domain, which is a homodimeric domain of Fc, can be substituted to change it into a heterodimeric structure in the form of a 'knob into hole', and these changed CH3 domains can be expressed at the ends of different scFvs to produce a minibody in the form of a heterodimeric scFv.

[0331] In the case of a bispecific or multispecific antibody based on Fab, individual Fabs for specific antigens can be combined with each other using a disulfide bond or a mediator to produce a heterodimeric Fab form, and by expressing scFvs for different antigens at the terminals of the heavy or light chains of a specific Fab, it can be produced to have two antigen-binding valencies, or by providing a hinge region between the Fab and scFv, it can be produced to have four antigen-binding valencies in a homodimeric form. In addition, a dual-target bibody in which the antigen-binding valencies are made three by fusing scFvs for different antigens to the light and heavy chain terminals of the Fab, and a tri-target bibody in which the antigen-binding valencies are made three by fusing different scFvs to the light and heavy chain terminals of the Fab, respectively, can be obtained by chemically conjugating three different Fabs.

[0332] For IgG-based bispecific or multispecific antibodies, a method for producing bispecific antibodies by crossbreeding mouse and rat hybridomas to produce hybrid hybridomas, also known as quadromas, has been known, as demonstrated by Trion Pharma. Furthermore, bispecific antibodies can be produced in the so-called "Holes and Knob" form, which shares the light chain while modifying some amino acids in the CH3 homodimeric domain of the Fc for different heavy chains to produce a heterodimeric form. In addition to heterodimeric bispecific antibodies, two different scFvs can be fused and expressed in the constant domains of the light and heavy chains of IgG, replacing the variable domains, to produce (scFv)4-IgG in a homodimeric form. In addition, ImClone reported the production of a bispecific antibody by fusing only a single variable domain for mouse platelet-derived growth factor receptor-α to the light chain amino terminus of IMC-1C11, a chimeric monoclonal antibody against human VEGFR-2. In addition, antibodies with multiple antigen-binding affinities for CD20 can be produced through the so-called 'dock and lock (DNL)' method using the dimerization and docking domain (DDD) of the R subunit of protein kinase A (PKA) and the anchoring domain of PKA.

[0333] A wide variety of recombinant antibody formats have been developed, including bivalent, trivalent, or tetravalent bispecific or multispecific antibodies. Examples include the bivalent, trivalent, or tetravalent antibodies described in International Patent Application Publications WO2001 / 077342, WO2009 / 080251, WO2009 / 080252, WO2009 / 080253, WO2009 / 080254, WO2010 / 112193, WO2010 / 115589, WO2010 / 136172, WO2010 / 145792, WO2010 / 145793, and WO2011 / 117330. An antibody being bivalent, trivalent, or tetravalent indicates that two or more binding domains, three or more binding domains, or four or more binding domains are present in the antibody molecule, respectively.

[0334] In a specific embodiment, the bispecific or multispecific antibody of the present invention comprises the anti-CD200R1 antibody or antigen-binding fragment, specifically an IgG complete antibody or fragment thereof, e.g., a single chain Fv, V H Domain and / or V L It can be included in the form of domain, Fab or (Fab)2.

[0335] In addition, antibodies targeting the CD200R1 and antibodies binding to other targets, for example, antibodies targeting one or more selected from the group consisting of IL-6, TNF-α, IL-4, IL-5, TSLP, and IFN-γ, specifically IgG complete antibodies or fragment forms thereof, for example, single-chain Fv, V H Domain and / or V L It can be included in the form of domain, Fab or (Fab)2.

[0336] The bispecific or multispecific antibodies of the present invention may provide additional binding specificities induced or mediated by other targets in addition to CD200R1.

[0337] For example, the bispecific antibody of the present invention can simultaneously target CD200R1 and one or more selected from the group consisting of IL-6, TNF-α, IL-4, IL-5, TSLP, and IFN-γ.

[0338] For example, the multispecific antibody of the present invention can simultaneously target two or more selected from the group consisting of CD200R1 and IL-6, TNF-α, IL-4, IL-5, TSLP, and IFN-γ.

[0339]

[0340] In the present invention, the antibody or antigen-binding fragment thereof may be characterized by specifically binding to CD200R1, and more preferably, may be characterized by specifically binding to human CD200R1.

[0341] In the present invention, the antibody or antigen-binding fragment may be characterized in that it does not cross-link to an immune-activating CD200R, for example, CD200RLa.

[0342] In the present invention, the antibody or antigen-binding fragment may be characterized by specifically binding to human or primate CD200R1, and may be characterized by not cross-linking to mouse CD200R1.

[0343] In the present invention, the antibody or antigen-binding fragment may be characterized by non-competitive binding to CD200, which is an innate antigen of CD200R1.

[0344] In the present invention, the antibody or antigen-binding fragment may be characterized by binding to CD200R1 and acting as an agonist or antagonist.

[0345] In the present invention, the antibody or antigen-binding fragment may preferably be characterized by binding to CD200R1 CD200R1 and acting as an agonist.

[0346] In the present invention, the antibody or antigen-binding fragment may be characterized by activating a downstream signaling pathway of CD200-CD200R1, thereby effectively suppressing an immune response.

[0347]

[0348] chimeric antigen receptor (CAR)

[0349] In another aspect, the present invention relates to a chimeric antigen receptor (CAR) comprising the antigen binding site.

[0350] A chimeric antigen receptor (CAR) is a synthetic construct designed to induce an immune response (either immune activation or suppression) against a target antigen and cells expressing that antigen. A CAR may comprise an extracellular domain comprising the antigen-binding site of the present invention, a transmembrane domain, and an intracellular signaling domain. Additionally, the CAR may further comprise a hinge domain and / or a co-stimulatory domain.

[0351] The above CAR may comprise the CDR, light chain and / or heavy chain of the anti-CD200R1 antibody of the present invention as an antigen recognition site in the extracellular domain.

[0352] In one embodiment, the antigen binding portion of the extracellular domain may be a scFv. In an scFv comprising the VH and VL domains of an antibody, the VH and VL domains may be linked via a linker.

[0353] The linker may be a peptide linker and may have a length of about 10-25 aa. For example, it may include hydrophilic amino acids such as glycine and / or serine.

[0354] The above linker is, for example, (GS)n , (GGS) n , (GSGGS) n or (G n S) m (n, m are 1 to 10 respectively) may be included, but the linker may be, for example, (G n S) m (n, m may be 1 to 10, respectively). Specifically, the linker may include GGGGS, for example, GGGGSGGGGSGGGGS of SEQ ID NO: 200 repeated three times.

[0355] In the present invention, the hinge domain may be selected from, for example, the CD8, CD4, or CD28 extracellular domain, the Fc region of an IgG1 antibody, or the extracellular domain of any of the TLR receptors known to those skilled in the art.

[0356] The transmembrane domain may be derived from a natural or synthetic source. If the source is natural, the domain may be derived from any membrane-bound protein or transmembrane protein. The transmembrane domain may comprise the alpha, beta, or zeta chain of the T-cell receptor, CD2, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, or ICOS. If the transmembrane domain is synthesized, it may comprise hydrophobic residues such as leucine and valine, or peptides containing phenylalanine, tryptophan, and valine at each terminus. A short oligo- or polypeptide linker of 2 to 10 amino acids in length may form a bond between the transmembrane domain and the cytoplasmic signaling domain of the CAR. Glycine-serine peptides can be used as linkers.

[0357] The intracellular signaling domain can induce activation of an immune activation or suppression function of an immune cell modified to express a CAR. The signaling domain can comprise a truncated fragment of the intracellular signaling domain sufficient to transduce an immune suppression function signal.

[0358] The signal transduction domain can induce activation of an immune activation or suppression function of an immune cell modified to express a CAR. The signal transduction domain can comprise a truncated fragment of an intracellular signal transduction domain sufficient to transduce an immune suppression function signal.

[0359] For example, the signal transduction domain regulates primary activation of the TCR complex in a stimulatory or inhibitory manner. A stimulatory primary cytoplasmic signaling sequence may contain a signaling motif known as an immunoreceptor tyrosine-based activation motif or ITAM. Examples of ITAM containing primary cytoplasmic signaling sequences include TCR zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, and CD66d.

[0360] In some cases, the cytoplasmic domain of the CAR may include a portion of the CD3 zeta chain and a costimulatory signaling domain. The costimulatory signaling domain refers to a portion of the CAR that includes the intracellular domain of a costimulatory molecule. For example, it may include ligands that specifically bind to CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and CD83.

[0361] As another example, the signal transduction domain can comprise an Fc signal transduction domain. The Fc signal transduction domain can be any one of the Fc-alpha, Fc-gamma, Fc-epsilon, Fc-mu, and Fc-delta receptors. For example, the Fc receptor signal transduction domain can comprise amino acids involved in interaction with Src (e.g., Fgr, Fyn, Hck, Lyn, Yes, and Src) and ZAP-70 family kinases, e.g., one or more ITAM domains (see, e.g., Sanchez-Mejorada et al. (1998) J. Leukocyte Biol. 63:531; Garcia-Garcia et al. (2002) J. Leukocyte Biol. 72:1092). In some embodiments, the Fc receptor signaling domain can comprise at least one ITAM domain, or substantially identical thereto, from any one of, for example, Fc-alpha, Fc-gamma, Fc-epsilon, Fc-mu, and Fc-delta receptors.

[0362] The cytoplasmic signaling sequence within the cytoplasmic signaling portion of the CAR may be linked via a peptide linker of 2 to 10 amino acids, for example, a glycine-serine containing peptide linker.

[0363] In the present invention, the nucleic acid encoding the CAR can be introduced so as to be expressed in immune cells, preferably regulatory T cells.

[0364] The type of each domain of CAR for use in the production of CAR-Treg can be easily selected from those known in the art (e.g., Cellular Immunology, 104220, etc.).

[0365]

[0366] From another perspective, the present invention relates to an immune cell into which the chimeric antigen receptor (CAR) has been introduced.

[0367] The above immune cells may be selected according to the desired therapeutic effect. For example, when the antibody or antigen binding portion of the present invention has a CD200R1 inhibitory effect, the immune cells may be selected from the group consisting of immune activated cells, for example, T cells, NK cells, cytokine-induced killer cells (CIKs), activated cytotoxic T lymphocytes (CTLs), macrophages, tumor-infiltrating lymphocytes (TILs), and dendritic cells. When the antibody or antigen binding portion of the present invention has a CD200R1 agonistic effect, the immune cells may be regulatory T cells, but are not limited thereto.

[0368]

[0369] therapeutic composition

[0370] In another aspect, the present invention relates to a composition for preventing or treating a disease comprising the antibody or an antigen-binding fragment thereof, a bispecific or multispecific antibody comprising the antibody or an antigen-binding fragment thereof, a chimeric antigen receptor comprising the antibody or an antigen-binding fragment thereof, or an immune cell comprising the chimeric antigen receptor.

[0371] In the present invention, when the antibody or antigen-binding fragment thereof, the bispecific or multispecific antibody including the antibody or antigen-binding fragment thereof, or the antibody or antigen-binding fragment thereof exhibits an antagonist effect, the disease may be a disease for which a therapeutic effect can be expected through activation of immunity, such as an infectious disease or cancer, but is not limited thereto.

[0372] In the present invention, when the antibody or antigen-binding fragment thereof, the bispecific or multispecific antibody including the antibody or antigen-binding fragment thereof, or the antibody or antigen-binding fragment thereof exhibits an agonist effect, the disease may be a disease for which a therapeutic effect can be expected through suppression of immunity, such as an immune disease or an inflammatory disease, but is not limited thereto.

[0373] The term “immune disease” of the present invention refers to a disease that can be caused directly by an abnormality in the immune system, and may correspond to any one selected from the group consisting of dermatitis, allergy, rhinitis, gout, inflammatory spondylitis, rheumatic fever, lupus, fibromyalgia, peritendinitis, type 1 diabetes, scleroderma, degenerative neurological disease, type 2 diabetes, silicosis, atherosclerosis, vitiligo, conjunctivitis, and autoimmune disease, but is not limited thereto.

[0374]

[0375] The term “autoimmune disease” of the present invention refers to a disease that occurs when immune cells in a living body recognize the living body’s own tissues or cells as antigens rather than external invading antigens and attack them, and the autoimmune disease includes rheumatoid arthritis, systemic scleroderma, insulin-dependent juvenile diabetes mellitus due to pancreatic cell antibodies, alopecia areata, psoriasis, pemphigus, asthma, aphthous stomatitis, chronic thyroiditis, some acquired aplastic anemias, primary cirrhosis, ulcerative colitis, Behcet’s disease, Crohn’s disease, silicosis, asbestosis, IgA nephropathy, post-streptococcal glomerulonephritis, Sjogren’s syndrome, Guillain-Barré syndrome, dermatomyositis, polymyositis, multiple sclerosis, autoimmune hemolytic anemia, autoimmune encephalomyelitis, myasthenia gravis, Grave’s hyperthyroidism, polyarteritis nodosa, ankylosing spondylitis, fibromyalgia, temporal arteritis, Wilson’s disease, It may be characterized by one or more of the following: Fanconi syndrome, multiple myeloma, and systemic lupus erythematosus, but is not limited thereto.

[0376] The term “inflammatory disease” of the present invention refers to a general term for diseases that have inflammation as a main cause and / or lesion, and may correspond to any one selected from the group consisting of edema, allergy, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, pharyngitis, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn’s disease, colitis, hemorrhoids, gout, ankylosing spondylitis, rheumatic fever, lupus, fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis of the shoulder joint, tendinitis, tenosynovitis, myositis, hepatitis, cystitis, nephritis, Sjogren’s syndrome, myasthenia gravis, and multiple sclerosis, but is not limited thereto.

[0377] The term “prevention” as used in the present invention means any act of suppressing or delaying the onset of an immune disease or an inflammatory disease by administering the pharmaceutical composition of the present invention.

[0378] The term "treatment" as used in the present invention means any act in which the symptoms of an immune disease or inflammatory disease are improved or beneficially changed by administration of the pharmaceutical composition of the present invention.

[0379] The pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, intradermal administration, topical administration, intranasal administration, intrapulmonary administration, and rectal administration.

[0380] Since proteins or peptides are digested upon oral administration, oral compositions must be formulated to coat the active agent or protect it from degradation in the stomach. Furthermore, the pharmaceutical composition can be administered by any device capable of transporting the active agent to the target cell.

[0381] The appropriate dosage of the composition of the present invention varies depending on factors such as the formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity, and a generally skilled physician can easily determine and prescribe a dosage effective for the desired treatment or prevention.

[0382] The pharmaceutical composition of the present invention can be manufactured in a unit dose form or can be manufactured by inserting it into a multi-dose container by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method that can be easily performed by a person having ordinary skill in the art to which the present invention pertains. In this case, the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or in the form of an extract, powder, suppository, powder, granule, tablet or capsule, and may additionally include a dispersing agent or stabilizer.

[0383]

[0384] Treatment method

[0385] From another aspect, the present invention relates to a composition for treating an immune disease or an inflammatory disease, comprising the antibody or an antigen-binding fragment thereof, a bispecific or multispecific antibody comprising the antibody or an antigen-binding fragment thereof, a chimeric antigen receptor, or an immune cell comprising the chimeric antigen receptor.

[0386] The present invention also relates to a method for treating an immune disease or an inflammatory disease, comprising a step of administering the antibody or an antigen-binding fragment thereof, a bispecific or multispecific antibody comprising the antibody or an antigen-binding fragment thereof, a chimeric antigen receptor, or an immune cell comprising the chimeric antigen receptor.

[0387] In another aspect, the present invention relates to the use of the antibody or an antigen-binding fragment thereof, a bispecific or multispecific antibody comprising the antibody or an antigen-binding fragment thereof, a chimeric antigen receptor or an immune cell comprising the chimeric antigen receptor for the prevention or treatment of an immune disease or an inflammatory disease.

[0388] In another aspect, the present invention relates to the use of the antibody or an antigen-binding fragment thereof, a bispecific or multispecific antibody comprising the antibody or an antigen-binding fragment thereof, a chimeric antigen receptor or an immune cell comprising the chimeric antigen receptor for the manufacture of a medicament for the prevention or treatment of an immune disease or an inflammatory disease.

[0389]

[0390] combination therapy

[0391] In another aspect, the present invention relates to a combined therapeutic use of the antibody or antigen-binding fragment thereof, a bispecific or multispecific antibody comprising the antibody or antigen-binding fragment thereof, a chimeric antigen receptor, or an immune cell comprising the chimeric antigen receptor.

[0392] The present invention may be administered in combination with another effective ingredient other than the antibody or antigen-binding fragment thereof, a bispecific or multispecific antibody comprising the antibody or antigen-binding fragment thereof, a chimeric antigen receptor, or an immune cell comprising the chimeric antigen receptor.

[0393] Examples of various drugs that can be used for immune or inflammatory diseases are well known in the art, and those skilled in the art can easily select and use drugs for combination administration based on this knowledge.

[0394]

[0395] Example

[0396] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples.

[0397] Example 1: Preparation of phage library (scFv)

[0398] To recover the previously constructed human-derived synthetic scFv library genes from a phagemid vector in the form of phages, six sub-libraries were constructed ((1) Bai, Xuelian & Kim, Jihye & Kang, Seungmin & Kim, Wankyu & Shim, Hyunbo. (2015). A Novel Human scFv Library with Non-Combinatorial Synthetic CDR Diversity. PloS one. 10. e0141045. 10.1371 / journal.pone.0141045., (2) Yang, Hye & Kang, Kyung & TCW, Julia & Shim, Hyunbo. (2009). Construction of a large synthetic human scFv library with six diversified CDRs and high functional diversity. Molecules and cells. 27. 225-35. 10.1007 / s10059-009-0028-9.) Samples were cultured in 400 ml of culture medium (SB / ampicillin / 2% glucose) for 2 hours. When the absorbance at O.D600 was 0.5-0.7, centrifugation was performed at 5000 g for 20 minutes, the supernatant was removed, and 10 was added to 400 ml of secondary culture medium (SB / ampicillin). 12Pfu (plaque forming unit) helper phage (VCSM13) was added and re-cultured for 1 hour. After that, kanamycin antibiotic (antibiotic gene introduced into helper phage) was added at a concentration of 70 ㎍ / ㎖, and the phage library was produced outside the host cells by shaking at 30℃ and 250 rpm for 16 hours. After that, the culture was centrifuged, and PEG 8000 (polyethylene glycol 8000) and NaCl were added to the supernatant, and the recombinant phage was precipitated by stirring at 4℃ for 2 hours. The pellet was precipitated by centrifugation at 12,000 g and 4 ° C for 30 minutes, and PBS was added to suspend it. PEG 8000 (polyethylene glycol 8000) and NaCl were added, and the phage library was recovered by adding PBS to the precipitated phage pellet after centrifugation at 15,000 g and 4 ° C for 30 minutes. The concentration of the amplified sublibrary was calculated by diluting the recovered phage, infecting TG1 cells, and culturing them on LB / ampicillin solid culture medium (Fig. 1).

[0399]

[0400] Example 2: Screening of anti-CD200R1-specific antibodies (scFv) using biopanning

[0401] Phage display panning was performed to select human antibodies that specifically bind to CD200R1.

[0402] Biopanning was performed using CD200R1-Fc protein as follows. The recombinant antigen used was Recombinant Human CD200R1 Fc Chimera Protein, CF (R&D systems, 3414-CD).

[0403] Antigen fixation biopanning: 1 ml of human CD200R1 Fc protein and negative Fc protein at a concentration of 1–5 μg / ml were coated in a 5 ml volume immunotube at 4°C for 16 hours, and blocked with 3% skim milk. After emptying the tube, the library (approximately 2.0 x 10 13 pfu) was placed in a tube coated with negative Fc protein and reacted at room temperature for 1 hour. This step removes phages that bind to proteins other than human CD200R1 from the antibody phage library, thereby preventing non-specific binding other than CD200R1.

[0404] Phages not bound to the negative Fc protein were recovered and bound to a plate coated with human CD200R1 Fc for 1 hour. After washing 3-9 times with PBST (Phosphate-buffered saline-0.05% Tween 20) solution to remove nonspecific binding, phage antibodies specific for human CD200R1 were recovered using IgG Elution Buffer (Thermo Scientific, 21028, Pierce™ IgG Elution Buffer, pH 2.0). The panning was performed up to a total of 4 times. The results of antigen-fixed bio-panning for rounds 1 to 4 are shown in Tables 1 to 5.

[0405]

[0406]

[0407]

[0408]

[0409]

[0410] Example 3: Affinity ELISA screening and sequence analysis of anti-CD200R1 specific antibodies (scFv)

[0411] To select a monoclonal antibody that specifically binds to CD200R1 from the phages recovered through the fourth round of panning, scFv screening was performed. Colonies from the final round of panning were obtained and inoculated into 96-well plates containing 200 μl of SB / ampicillin culture medium and cultured at 37°C for 3-4 hours. Afterwards, each well was treated with a final concentration of 1 mM IPTG (Isopropyl β-D-1-thiogalactopyranoside) to induce scFv-pIII protein expression and cultured at 30°C for 16 hours. The cultured plates were centrifuged at 4,000 rpm for 15 minutes, the supernatant was removed, and 40 μl of TES (50 mM Tris, 1 mM EDTA, 20% sucrose, pH 8.0) solution was added to each well to recover the phage particles, and the cells were lysed for 30 minutes at room temperature. Afterwards, the cells were lysed by treating with 60 μl of 0.2XTES solution and incubating at 4°C for 2 hours, and then the plate was centrifuged at 4,000 rpm for 15 minutes to recover the supernatant.

[0412] Human CD200R1 (R&D systems, 3414-CD), Negative Fc protein, was coated with the supernatant in each well of a 96-well plate. The supernatant was allowed to bind at room temperature for 2 hours, and then washed four times with 0.05% PBST and distilled water. Afterwards, HRP-conjugated anti-HA antibody capable of binding to the HA tag was used, and the cells were allowed to bind at room temperature for 1 hour, and then washed four times with PBST and distilled water.

[0413] After adding TMB Substrate solution (Thermo Scientific, 34029, 1-Step™ Ultra TMB-ELISA Substrate Solution) to develop color, the color reaction was stopped with Stop Solution (Invitrogen, SS04, ELISA Stop Solution), and the absorbance was measured at OD 450 nm. Through ELISA, 15 antibody clones that bind only to human CD200R1 but not to Negative Fc Protein were selected, and the CDR sequences of each antibody are as shown in Tables 6 and 7, and the amino acid sequences of the heavy and light chain variable regions are as shown in Tables 8 and 9.

[0414]

[0415]

[0416]

[0417]

[0418]

[0419]

[0420] Example 4: Analysis of CD200R1-specific binding ability of anti-CD200R1 antibodies discovered by phage display (ELISA)

[0421] Human CD200R1 (R&D systems, 3414-CD) and Mouse CD200R1 Protein (R&D systems, 2554-CD) were coated on 96-well plates at a concentration of 2 μg / mL at 4°C for 16 hours, and blocked with 3% skim milk. Afterwards, each antibody was treated at a concentration of 300 nM, 60 nM, 12 nM, 2.4 nM, 0.48 nM, 0.096 nM, and 0.0192 nM and reacted at room temperature for 2 hours.

[0422] After washing with PBST and distilled water, the mixture was bound for 1 hour at room temperature with a goat-derived HRP-conjugated anti-human antibody (Invitrogen, 31482, Goat anti-Human IgG F(ab')2 Secondary Antibody, HRP), and then washed again with PBST and distilled water. After adding TMB Substrate solution (Thermo Scientific, 34029, 1-Step™ Ultra TMB-ELISA Substrate Solution) to develop color, the color reaction was stopped with a stop solution (Invitrogen, SS04, ELISA Stop Solution), and the absorbance was measured at OD 450 nm. It was confirmed that the anti-CD200R1 antibody of the present invention does not exhibit cross-binding ability between human CD200R1 and mouse CD200R1 (Fig. 2).

[0423]

[0424] Example 5: Competition binding assay with human CD200 (ELISA)

[0425] Human CD200R1 (R&D systems, 3414-CD) recombinant protein was coated on a 96-well plate at a concentration of 2 μg / mL at 4°C for 16 hours, and blocked with 3% skim milk for 1 hour. Then, each antibody was treated at a concentration of 500 nM, 166.67 nM, 55.56 nM, 18.52 nM, 6.17 nM, 2.06 nM, and 0.69 nM and reacted at room temperature for 30 minutes. Then, rhCD200-Fc (R&D systems, 2724-CD) recombinant protein was additionally treated to a final concentration of 1 μg / mL and bound at room temperature for 1 hour and 30 minutes. After washing with PBST and distilled water, Human CD200 Biotinylated Antibody was treated at a concentration of 0.5 μg / mL (R&D systems, BAF2724). After washing with PBST and distilled water, the mixture was bound for 1 hour at room temperature with Pierce™ High Sensitivity Streptavidin-HRP (Thermo scientific, 21130), and then washed again with PBST and distilled water. After adding TMB Substrate solution (Thermo Scientific, 34029, 1-Step™ Ultra TMB-ELISA Substrate Solution) to develop color, the color reaction was stopped with stop solution (Invitrogen, SS04, ELISA Stop Solution). The absorbance was measured at OD 450 nm to confirm whether the discovered clones competitively bind to CD200.

[0426] As illustrated in Figure 3, except for P001002, none of the substances discovered in the present invention exhibited competitive binding. In the case of P001002, it exhibited an IC50 value of 11.5 nM, demonstrating an inhibitory (antagonistic) effect that blocks CD200R1.

[0427]

[0428] Example 6: Screening of anti-CD200R1 specific antibodies using hybridomas

[0429] To screen for anti-CD200R1 antibodies using hybridoma technology, immunization was performed using the human CD200R1 recombinant protein (Abclon-MANI protocol applied). Five weeks after immunization, a pool of clones that bound to human CD200R1 was selected through fusion ELISA. Clones showing high ELISA values ​​(OD values) to the antigen were cloned into single clones, and finally, hybridoma clones showing antigen binding were selected (Figure 4). The clones were 1F1, 1H10, 3G4, 5E9, 6A8, 6A10, and 6C3, and ELISA binding to the antigen was analyzed with an ELISA OD of approximately 1.5 or higher (negative antigen, 0.04 or lower). Based on this, the following cloning was performed to obtain antibody sequences for the hybridoma clones screened through immunization. RNA was isolated using a commercially available RNA extraction kit (Invitrogen, 12183555, TRIzol™ Plus RNA Purification Kit). Single-stranded DNA was synthesized using a PCR cDNA synthesis kit (Takara, 634925, SMARTer® PCR cDNA Synthesis Kit) and the following primers: SMART_F (SEQ ID NO: 201): 5'-AAG CAG TGG TAT CAA CGC AGA GTA CGC GGG-3', SMART_CDS_F (SEQ ID NO: 202): 5'-AAG CAG TGG TAT CAA CGC AGA GTA CTT TTT TTT TTT TTT TTT TTT TTT TTT TTT TVN-3' (V= A, C, G; N = A, C, G, T).

[0430] First-strand cDNA synthesis was performed using a synthesis kit (Invitrogen, 18091050, SuperScript™ IV First-Strand Synthesis System), and synthesis into ss-cDNA was performed with Pfu-X DNA Polymerase (Solgent, SPX16-R250, Solg™ Pfu-X DNA Polymerase).

[0431] The base sequences of the heavy and light chain variable regions of the antibody were determined using the heavy chain variable region primers Hybridoma_F (SEQ ID NO: 203) (5'- AAG CAG TGG TAT CAA CGC AGA GT -3') and mIgG2a_1 & mIgG2b_1 (SEQ ID NOs: 204 and 205) (5'- CAG GGG CCA GTG GAT AGA CCG ATG -3', 5'- CAG GGG CCA GTG GAT AGA CTG ATG -3'), and the light chain variable region primers were Hybridoma_F (5'- AAG CAG TGG TAT CAA CGC AGA GT -3') and mckappa_1_R (SEQ ID NO: 206) (5'- GGA TGG TGG GAA GAT GGA TAC AGT TGG TG -3') or mckappa_2_R (SEQ ID NO: 207) (5'- TTA ACA CTC ATT CCT GTT GAA GCT CTT GAC -3') was used. The mixed sample was placed in a PCR machine, and after amplification, the product was confirmed by electrophoresis on an agarose gel and purified using a gel extraction kit (Macherey-Nagel, 740609.50, NucleoSpin Gel and PCR Clean-up). The amplified PCR product was ligated to the Topo vector using a kit (Invitrogen, 45-0245, Zero Blunt™ TOPO™ PCR Cloning Kit, without competent cells), and each heavy and light chain expression plasmid was electroporated for transformation. The resulting colonies were collected, and the plasmids were purified using a miniprep kit (QIAGEN, 27104, QIAprep Spin Miniprep Kit).

[0432] The CDR sequences of each antibody are shown in Tables 10 and 11, and the amino acid sequences of the heavy and light chain variable regions are shown in Tables 12 and 13.

[0433]

[0434]

[0435]

[0436]

[0437] Example 7: Humanization Engineering of Anti-CD200R1 Antibody

[0438] The mouse-derived anti-CD200R1 antibody OX108 (P001017, NCBI data base ID: 3DGG_A and 3DGG_B) clone was humanized for development and improvement for therapeutic purposes. The variable regions of the light and heavy chains of the P001017 clone were analyzed (Kabat numbering, Chothia numbering), and the CDR of P001007 was compartmentalized and grafted onto human FRs, thereby performing CDR-grafting. In addition, a homology-based framework (FR) was used or a human framework (FR) that is widely introduced into therapeutic antibodies was engineered (fixed framework) (Fig. 5).

[0439] Each light chain and heavy chain is as shown in Tables 14 and 15 below, and humanized antibody engineering was performed through each combination. Table 16 lists the sequences of antibodies discovered through humanized engineering, and Table 17 lists the CDR sequences of each antibody.

[0440]

[0441]

[0442]

[0443]

[0444] As shown in FIGS. 6 and 7, binding ability analysis for human CD200R1 was performed through ELISA for antibodies to which humanized engineering was applied, and the P001018 clone showed specific binding ability similar to that of P001017 (parent antibody), and in silicohumanness analysis confirmed that the humanization value met the standard range, thereby reducing the risk of immunogenicity or ADA.

[0445]

[0446] Example 8: Affinity Engineering for Anti-CD200R1 Humanized Antibodies

[0447] For the humanized antibody P001018, affinity improvement engineering was performed using phage display technology. A phagemid vector displaying the P001018 scFv fragment (heavy chain variable region; VH, light chain variable region; VL) on the surface of M13 bacteriophage was constructed and used as a library template. For affinity maturation, CDRs H1, H2, H3 and CDRs L1, L2, L3 were selected based on the Kabat numbering of the antibody, and a P001018 mutant library was constructed using primers containing the NNK degeneration codon for each CDR. For each library, the biopanning (antigen fixation panning) described above was performed 3-4 times, and based on this, antibodies with increased affinity compared to the P001018 clones were secured through ELISA-based affinity screening. As shown in Figures 8 and 9, the major clones with improved affinity were identified as H3_Y102K, H3-Y102T, L3-R92H, L3-R92S, L3-L94S, L3-L94H, L3-L95D, L3-T96R (Kabat numbering), etc., and these were confirmed through antigen binding ability (ELISA) and cell binding ability analysis (FACS). The sequences and CDR sequences of Scfv with each mutant sequence are as shown in Tables 18 to 20.

[0448]

[0449]

[0450]

[0451]

[0452] The obtained clones were produced as antibodies and their affinity for human CD200R1 was evaluated through ELISA. Based on this, variants with excellent affinity were combined to perform secondary engineering (Table 21).

[0453]

[0454] The amino acid sequences and CDR sequences of the heavy chain variable and light chain variable regions of each antibody with improved affinity are shown in Tables 22 to 25.

[0455]

[0456]

[0457]

[0458]

[0459]

[0460] The secondary engineered antibodies were evaluated by ELISA in the same manner as in the above examples. Finally, various affinity-matured mutants were identified through antibody sequence analysis. As illustrated in Figure 10, the obtained P001018 mutants exhibited significantly increased specific binding to the human CD200R1 recombinant protein compared to the parent antibody.

[0461]

[0462] Example 9: Mammalian cell expression and purification of anti-CD200R1 antibody

[0463] All clones obtained in the above examples were subjected to cloning and production processes to produce monoclonal antibodies in the form of immunoglobulin (IgG). To construct a heavy chain expression vector, DNA encoding the heavy chain, including the heavy chain variable region and constant region, was cloned into the pOptivec vector. In addition, to construct a vector expressing the light chain, DNA encoding the light chain, including the light chain variable region and light chain constant region, was cloned into the pcDNA3.3 vector.

[0464] The light and heavy chain expression vectors were transiently transfected to express and purify proteins. Expi293F suspension cells (Gibco, A14527, Expi293F™ Cells) growing suspended in Expi293 Expression medium (Gibco, A1435101, Expi293™ Expression Medium) were transfected with a mixture of plasmids, Opti-MEMⅠ (Gibco, 31985070, Opti-MEM™ I Reduced Serum Medium), and ExpiFectamine293 (Gibco, 100014995, ExpiFectamine™293). After culturing for 5 days at 8% CO2, 37°C, and 130 rpm, the proteins were purified from the cell culture supernatant. The culture medium was passed through a column (GE healthcare, 17-5438-01, MabSelect™ SuRe) to allow the expressed antibody to bind to the column. Afterwards, the antibody was eluted with IgG Elution Buffer (Thermo Scientific, 21028, Pierce™ IgG Elution Buffer, pH 2.0), and the eluted antibody fraction was concentrated using an Amicon Ultra 30kDa tube (Merck Millipore, UFC903024, Amicon® Ultra-15 Centrifugal Filter Unit) by exchanging the buffer with PBS (pH 7.4).

[0465] Purified anti-CD200R1 antibody was quantified using absorbance and extinction coefficient at a wavelength of 280 nm.

[0466]

[0467] Example 10: Human and monkey cross-linking assay (ELISA) of CD200RLa isoform, an immune-activating CD200R.

[0468] Human CD200RLa (Sino Biological, 11620-H08H) and monkey CD200RLa (Sino Biological, 11576-C02H) recombinant proteins were coated on 96-well plates at a concentration of 2 μg / mL at 4°C for 16 hours, and blocked with 3% skim milk for 1 hour. Then, each antibody was treated at a concentration of 300 nM, 60 nM, 12 nM, 2.4 nM, 0.48 nM, 0.096 nM, and 0.0192 nM and reacted at room temperature for 2 hours. After washing with PBST and distilled water, the mixture was bound for 1 hour at room temperature using goat-derived HRP-conjugated anti-human antibody (Invitrogen, 31482, Goat anti-Human IgG F(ab')2 Secondary Antibody, HRP), and then washed again with PBST and distilled water. After color development by adding TMB Substrate solution (Thermo Scientific, 34029, 1-Step™Ultra TMB-ELISA Substrate Solution), the color reaction was stopped with stop solution (Invitrogen, SS04, ELISA Stop Solution), and the discovered clones were confirmed to have no cross-linking ability to human CD200RLa and cyno CD200RLa through absorbance measurement at OD 450 nm (Fig. 11).

[0469]

[0470] Example 11: Analysis of CD200R1 binding domain of anti-CD200R1 antibody using human-mouse CD200R1 hybrid protein (ELISA)

[0471] The recombinant proteins of human CD200R1 extracellular protein Ig-like V-type domain and Ig-like C2-type domain were prepared here as human, mouse (HM hybrid domain) and mouse, human (MH hybrid domain), respectively, and coated on a 96-well plate at a concentration of 1 μg / mL at 4°C for 16 hours, and blocked using 3% skim milk. Afterwards, each antibody was treated at a concentration of 300 nM, 60 nM, 12 nM, 2.4 nM, 0.48 nM, 0.096 nM, and 0.0192 nM and reacted at room temperature for 2 hours. After washing with PBST and distilled water, the mixture was bound for 1 hour at room temperature with a goat-derived HRP-conjugated anti-human antibody (Invitrogen, 31482, Goat anti-Human IgG F(ab')2 Secondary Antibody, HRP), and then washed again with PBST and distilled water. After color development with TMB Substrate solution (Thermo Scientific, 34029, 1-Step™Ultra TMB-ELISA Substrate Solution), the color reaction was stopped with a stop solution (Invitrogen, SS04, ELISA Stop Solution), and the absorbance was measured at OD 450 nm. The anti-CD200R1 antibody clones binding to each domain were analyzed through ELISA, and the results are as shown in Figure 12.

[0472]

[0473] Example 12: CD200R1-expressing cell binding ability of anti-CD200R1 antibodies selected using a multi-faceted antibody discovery technology

[0474] The binding ability of substances discovered using a unique multifaceted antibody discovery technology was confirmed in HH (CRL-2105) cells that endogenously express CD200R1 and Jurkat-CD200R1 (Source: DiscoverX) cells created by intranuclear injection of CD200R1 cDNA.

[0475] HH and Jurkat-CD200R1 cells were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated FBS and 1% Penicillin / Streptomycin (P / S), washed by centrifugation at 130 g for 5 min, and seeded at 1 × 10 per well in Flow Cytometry Staining Buffer (Invitrogen, #00-4222-26) or FACS buffer. 5 Cells / 100 μl were dispensed into 96-well round bottom plates (SPL, #34296). Drug treatment was performed at a concentration of 500 nM with 16 substances and the positive control LY3454738 (US 2020 / 0087395, I-4P, Eli Lilly) in the IgG1 form. After incubation for 1 hour at 4°C, the cells were treated with Alexa-647 Goat anti-human IgG (H+L) cross-adsorbed secondary antibody (Invitrogen, #A21445) and incubated for an additional 30 minutes at 4°C. After washing twice with FACS buffer, flow cytometry analysis was performed using a Novocyte Flow cytometer (Agilent).

[0476] As shown in Figure 13, Mean Fluorescence Intensity (MFI) measures the fluorescence intensity of each antibody tagged with Alexa-647 secondary antibody, and is a value normalized by the fluorescence expression of each antibody based on P001017 (chimeric OX108). In two cell lines, six effective substances, including P001002, P001004, P001006, P001008, P001009, and P001018, showed good binding ability of more than 50%. In addition, among the seven substances discovered by hybridoma technology, ch1F1 and ch6C3 clones also showed significant binding ability in two cell lines.

[0477]

[0478] Example 13: Cell binding capacity of IgG4, LALAPG mutant form of anti-CD200R1 antibody

[0479] The cell binding ability was confirmed in the same manner as in Example 12, and for the six effective substances primarily selected in Example 12, the isotype was changed to IgG4 or the LALAPG genetic mutation was performed, and the binding ability was confirmed in the two cell lines mentioned above.

[0480] As illustrated in Figure 14, the remaining five effective substances, excluding P001002, exhibited excellent binding capacity regardless of isotype. Among the antibodies discovered using phage display technology, P001009, which exhibited the highest binding capacity, demonstrated the highest efficacy.

[0481]

[0482] Example 14: Affinity Improvement and Sequence Confirmation of Anti-CD200R1 Antibody

[0483] In order to improve the affinity of the antibody obtained in Example 13, mutations were performed to improve the affinity, enhance cross-species binding ability, and remove unwanted PTM sites. In particular, affinity improvement was performed based on the P001009 antibody sequence that showed excellent efficacy in Example 13, and the CDR, VH, and VL sequences of the affinity-improved antibody are as shown in Tables 26 to 29.

[0484]

[0485]

[0486]

[0487]

[0488] First, we identified sequence motifs in the antibody sequence that are at risk of deamidation and isomerization during and after production under stressed conditions. The locations of these motifs, numbered according to Kabat Numbering, are as follows: LC N30 (P019001v3), LC N31 (P019001v4), LC D51, LC S52 (P019001v1, P019001v2), LC D92, LC D93 (P019001v2), and LC S94 (P019001v1).

[0489] It is known that substituting N or D in sequences that are at risk of deamidation and isomerization can significantly impair the affinity of antibodies (Journal of Pharmaceutical Sciences, 105(2), 512-518).

[0490] Therefore, the LC D51 and LC D92 sequences were not substituted during the optimization process. However, since LC N30 and LC N31 can play an important role in the specific binding of antibodies as paratopes, the sequences were substituted and optimized. Through rational design, LC S52 and LC S94 were substituted with K and R, respectively, to derive P001009v1, and LC S52 and LC D93 were substituted with K and R, respectively, to derive P001009v2. Additionally, P001009v3, in which LC N30 was substituted with S, and P001009v4, in which LC N31 was substituted with K, were derived and produced, and the binding ability to human, mouse, and monkey CD200R1 was analyzed by ELISA (Fig. 15). As shown in Fig. 15, the human and monkey CD200R1 binding ability of P019001v1 was improved compared to the existing P019001. For P019001v2, binding to monkey CD200R1 was significantly improved compared to P019001, but binding to human CD200R1 was reduced. P019001v3 and P019001v4 also improved binding to monkey CD200R1, but decreased binding to human CD200R1. Both P019001 and its variants showed very weak binding to mouse CD200R1 in the measurement range up to 300 nM of the antigen.

[0491]

[0492] Example 15: Analysis of CD200R1-specific binding capacity of anti-CD200R1 antibodies (SPR)

[0493] The specific binding ability of the antibodies derived in Example 14 (P001009_wt, P001009_v1, P001009_v2, P001009_v3, P001009_v4) to CD200R1 was analyzed using surface plasmon resonance (SPR). For the experiment, 30 μg / mL of anti-histidine antibody was conjugated to a CM5 biacore chip via amine bond while flowing at 10 μl / min (10,000 RU). After that, 0.25 μg / mL of human or cynomolgus CD200R1 with doubly His-tags was captured on the completed chip for 60 seconds, and the binding ability of each antibody was analyzed. All experiments were performed by associating the antibodies for 120 seconds and then dissociating them for 600 seconds. The derived results were graph-fitted using a 1:1 Langmuir binding kinetic model (Fig. 16), and the kinetics of each antibody were calculated. The kinetics of the parent antibody and the improved antibody with human CD200R1 are shown in Table 30 below. The kinetics of the parent antibody and the improved antibody with cynomolgus CD200R1 are shown in Table 31 below.

[0494]

[0495]

[0496] Example 16: Specific binding ability of anti-CD200R1 antibodies to cell surface-expressed CD200R1

[0497] Although the antigen binding ability of the selected anti-CD200R1 antibodies in the above examples was confirmed, it is necessary to confirm whether excellent binding ability is also observed in cell lines with high CD200R1 expression. The binding ability was confirmed in HH, an endogenous T cell cell line with high endogenous expression of CD200R1, and two additional overexpressing cell lines: U937-CD200R overexpressing cells, which were generated by intranuclear injection of human CD200R1 cDNA into the monocytic cell line U937 (CRL-1593.2) (Source: UMC Utrecht, the Netherlands), and Jurkat-CD200R overexpressing cells, which were also engineered in a similar manner.

[0498] All cell lines were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated FBS and 1% Penicillin / Streptomycin (P / S), and cell binding ability was confirmed using the same method as Example 12. In two additional wells, 10 μl of mouse IgG1K (BD, #555751) and 5 μl of CD200R1 (Biolegend, #329308) commercial antibody were treated to confirm CD200R1 expression on the cell line surface for cell QC.

[0499] Specific binding was confirmed using P001009 WT and antibody-optimized variants, P001009v1, P001009v2, P001009v3, and P001009v4. The maximum concentration was 100 nM, and the pre-seeded cells were treated with 10 nM, 1 nM, 100 pM, 10 pM, and 1 pM antibodies at 10-fold dilution. After incubation for 1 h at 4°C, the cells were treated with Alexa-647 Goat anti-human IgG (H+L) cross-adsorbed secondary antibody (Invitrogen, #A21445) and incubated for an additional 30 min at 4°C. After washing twice with FACS buffer, flow cytometry was performed using a Novocyte Flow cytometer (Agilent). Using GraphPad Prism software, log(agonist) vs. response - Variable slope nonlinear graph model, as shown in Table 32, EC 50 The value was confirmed.

[0500]

[0501] For Jurkat-CD200R1, P001009v1 showed the best binding ability. In U937-CD200R1 and HH cell lines, only the binding ability of P001009v1 was additionally confirmed. All were 10 -10 At the M level, the candidate substances showed excellent binding ability to receptors expressed on various cells (Fig. 17).

[0502]

[0503] Example 17: Confirmation of the anti-inflammatory effect of anti-CD200R1 antibody

[0504] To confirm the binding ability of the candidate substance to the U937-CD200R1 overexpressing cell line and to verify its efficacy, the anti-inflammatory effect of the anti-CD200R1 antibody was analyzed. First, 5 x 10 6U937-CD200R1 cells were placed in 12 ml of medium, treated with Phorbol 12-myristate 13-acetate (Sigma Aldrich, #P1585) at a concentration of 30 ng / ml, and incubated at 37°C and 5% CO2 for 24 h. After the incubation, the medium was changed to RPMI 1640 medium containing only 10% heat-inactivated FBS, and 5 x 10 6 Only the dog cells were maintained at 37°C, 5% CO2 for 24 hours.

[0505] 1 x 10 per well in a 96-well round bottom plate (SPL, #34296) 5 Cells were aliquoted in duplicate at 50 μl. P001009 WT, P001009v1, and the previously published CD200R antibody LY3454738 (US 2020 / 0087395, I-4P, Eli Lilly) as a positive control were used in this experiment. Starting at a maximum concentration of 100 nM, the cells were diluted 10-fold and treated with the drug at 10 nM, 1 nM, 100 pM, 10 pM, and 1 pM, respectively. Additional cells were treated with 100 nM of hIgG4 kappa isotype control (Crownvivo, #C0004) as a negative control. For untreated cells, the same amount of medium (RPMI 1640 containing 10% heat-inactivated FBS) was dispensed and incubated at 37°C, 5% CO2 for 1 hour. To induce an inflammatory response in drug-treated cells, 10 μl per well of Lipopolysaccharide from Salmonella typhosa (Sigma Aldrich, #L7895) at a concentration of 1 μg / ml was treated. One well was not treated with LPS to determine the ability to induce inflammatory cytokines. After mixing well, the cells were incubated at 37°C, 5% CO2 for 24 hours.

[0506] After centrifugation at 1100 g for 2 minutes, images of the pellets before and after LPS treatment were captured using a microscope (Carl Zeiss, AXIO VERT.A1). After LPS treatment, the pellets appeared as scattered debris (Fig. 18B) rather than uniform spheroids (Fig. 18A). After confirming this under a microscope, the supernatant was secured and analyzed for inflammatory cytokines such as TNF-α and IL-6 using an EnVision® multimode plate reader (PerkinElmer). A bead-based cytokine assay was used with the AlphaLISA immunoassay of the EnVision® instrument. For TNF-α, the TNF-α (human) AlphaLISA Detection Kit, 500 assay points (PerkinElmer, #AL208C) was used, and for IL-6, the IL-6 (human) AlphaLISA Detection Kit, 500 assay points (PerkinElmer, #AL223C) was used to determine cytokine levels according to the concentration of each antibody.

[0507] Table 33 shows the results of confirming the TNF-α inhibitory effect of three drugs, and Table 34 shows the results of confirming the IL-6 inhibitory effect (Fig. 19). By measuring cytokine levels according to drug concentration, IC 50 The results of the calculation are shown in Table 35.

[0508]

[0509]

[0510]

[0511] When the negative control group, hIgG4, was treated at the highest concentration, the levels of TNF-α and IL-6 were high at 5 ng / ml and 3.5 ng / ml, respectively, but were confirmed to be suppressed when the corresponding drugs were treated. Among them, P001009v1 maintained low levels of inflammatory cytokines even at low drug concentrations at the nanomolar (nM) level, indicating that the antibody of the present invention exhibits an excellent inflammation suppression effect.

[0512]

[0513] Example 18: Confirmation of the effect of anti-CD200R1 antibody on Dok2 protein phosphorylation.

[0514] The Dok2 adaptor protein is phosphorylated by the CD200-CD200R1 interaction, which inhibits mast cell degranulation or inflammatory cytokine secretion through downstream signaling. The Dok2 gene, like CD200R1, was found to have a high heritability in the genomes of atopic dermatitis patients (Mucha et al., 2020), and a drug evaluation platform was established based on this.

[0515] Jurkat-CD200R1 cells were maintained as in Example 17 and dispensed in triplicate into CulturPlate-384, a White Opaque 384-well microplate (PerkinElmer, #6007688) at 8,000 cells / 32 μl per well. AssayComplete Cell Plating 0 Reagent (DiscoverX, #93-0563R0A) media was used for cell dispensing and antibody dilution. The dispensed cells were incubated at 37°C and 5% CO2 for 30 minutes.

[0516] During the reaction, the Fc capture antibody, Anti-human IgG (Fc specific) antibody produced in goat (Sigma Aldrich, #I2136, 2.3 mg / ml), was diluted in AssayComplete media and reacted at 37°C, 5% CO2 for 30 minutes. After incubation of both the plate containing the cells and the Fc capture antibody, the Fc capture antibody was treated at 50 μg / ml per well. The reaction was carried out for 3 hours at 37°C, 5% CO2. After cross-linking by the Fc capture antibody, a total of three types of antibodies were treated as in Example 17, starting from the highest concentration of 50 nM and diluted 2-fold, and treated at 25 nM, 12.5 nM, 6.25 nM, 3.12 nM, 1.56 nM, 0.78 nM, 0.39 nM, 0.20 nM, 0.098 nM, and 0.049 nM. After treatment, the reaction was allowed to proceed for an additional 2 hours at room temperature.

[0517] To confirm the response of the Jurkat-CD200R1 reporter cell line to the treated antibody, the PathHunter Detection kit (DiscoverX, #93-0001) was used. The final data were read using the Infinite M200 Pro Plate reader (Tecan) to measure the luminescence intensity from phosphorylated Dok2. Random Luminescence Unit (RLU) is an arbitrary unit representing luminescence and is a value converted to the signal detected by the cross-linked Fc capture antibody. Table 36 shows the RLU values ​​according to the drug treatment concentration, and Table 37 shows the EC value for the degree of signal transduction by the Dok2 protein. 50 It is expressed as a value.

[0518]

[0519]

[0520] As shown in Figure 20, no reactivity was observed in the positive control group, but luminescence due to phosphoDok2 was observed in the P001009 WT and P001009v1 antibodies, indicating that immune signaling is occurring efficiently at a lower level.

[0521]

[0522] Example 19: Confirmation of the inhibitory effect of anti-CD200R1 antibody on type 1 and type 2 inflammatory cytokines in nasal polyp patient specimens.

[0523] The efficacy of anti-CD200R1 was confirmed by drug treatment in patient specimens with chronic rhinosinusitis with nasal polyps.

[0524] After chopping and mincing the specimen, the m_lung_02 protocol was run twice more using gentleMACS (Miltenyi Biotec) to fragment the cells. After centrifugation at 1500 rpm for 3 minutes to ensure that all tissues formed a pellet, the pellet was added to RPMI media + 10% FBS at a 1:3 ratio. The pellet was thoroughly mixed with the medium and dispensed into a 96-well u-bottom plate at 100 μl per well, in triplicate for each drug. To establish the screening assay, the results were first obtained using Dexamethasone (a steroid-based positive control drug), and subsequently treated with anti-CD200R1 antibody (P001009v1) and other drugs used for the disease. All antibody-based drugs were treated at 100 nM, and steroid drugs such as Dexamethasone were treated at 20 μM.

[0525] After drug treatment, the cells were incubated at 37℃ for 1 hour, and 4 μl of Cell stimulation cocktail 500X (Invitrogen #00-4970-03) was diluted 10-fold and dispensed per well to increase the overall cytokine levels of the samples and mixed. After incubation at 37℃ for 24 hours, the supernatant was collected by centrifugation. The cytokine levels in the supernatant were checked using the Human Th1 / Th2 Cytokine Cytometric Bead Array (CBA) Kit (BD, #550749) and the different reactivity to the drug was confirmed for each sample. Among the 10 patient samples tested, 3 samples showed resistance and did not suppress the levels of Th2 cytokines (IL-5, IL-4) associated with allergic reactivity when treated with DUPIXENT®, a drug used as a conventional treatment for atopic dermatitis and allergic diseases. In the same sample, the anti-CD200R1 antibody of the present invention exhibited excellent immunosuppressive activity (Figs. 21 and 22).

[0526]

[0527] Example 20: Confirmation of inflammation inhibition by anti-CD200R1 antibody in an animal model of multiple sclerosis (in vivo)

[0528] An in vivo multiple sclerosis animal model was constructed, and the anti-CD200R1 antibody (P0001009v1) of the present invention was used to confirm the anti-inflammatory response. A 10-week-old female C57BL / 6J multiple sclerosis animal model was used, and the model was constructed using a Hooke kit (EK-2110, Hooke Laboratories, USA). MOG35-55 / CFA emulsion from the Hooke kit was injected subcutaneously into the back and neck of the experimental animals, each in a volume of 100 μL. Two hours later, pertussis toxin (PTX) was administered intraperitoneally for the first time, and 24 hours later, pertussis toxin (PTX) was administered intraperitoneally again. The body weights of the mice were measured once a day, and scores were calculated based on the symptoms of multiple sclerosis. Scoring was performed as follows.

[0529] 0: Asymptomatic;

[0530] 0.5: The tip of the tail is paralyzed;

[0531] 1.0: The entire tail is paralyzed;

[0532] 1.5: When I place the mouse on the stainless steel top that covers the cage and let it walk, one of its hind legs intermittently falls down;

[0533] 2.0: When holding the mouse upside down by the tail, the hind legs do not extend outward;

[0534] 2.5: When walking on the stainless steel top, the mouse's hind legs keep falling off, but it can barely pull the legs up;

[0535] 3.0: When walking on a stainless steel top, the hind legs that fell off cannot be lifted up and the feet just shake;

[0536] 3.5: The hind legs are completely paralyzed and cannot move at all;

[0537] 4.0: The front legs are weak and cannot hold the stainless steel top;

[0538] 4.5: Euthanasia is unavoidable due to death or extreme weight loss (30%).

[0539] To confirm these scores, the animals were placed on a wire mesh or held upside down by the tail to check for symptoms. Anti-CD200R1 antibody administration was initiated when more than 50% of all animals showed symptoms. The control group was administered PBS, and the treatment groups were administered intravenously at doses of 5 mg / kg and 30 mg / kg, twice per week for a total of four times. After the experiment, statistical analysis was performed using a two-way ANOVA with repeated measures.

[0540] In the anti-CD200R1 antibody treatment group, the score was maintained at the level of 1.0 after repeated administration and no symptoms of multiple sclerosis were observed. However, in the negative control group, the average score was maintained at 2.5 or higher, confirming the therapeutic effect on multiple sclerosis.

[0541]

[0542] Example 21: Confirmation of inflammation inhibition by anti-CD200R1 antibody in an animal model of contact dermatitis (in vivo)

[0543] An in vivo contact dermatitis animal model was established to evaluate the anti-inflammatory efficacy of anti-CD200R1 antibodies. Ten-week-old female C57BL / 6 mice were used as the contact dermatitis animal model. The animals were anesthetized, their abdominal hairs were removed, and the following day, the depilated abdomen was sensitized with 3% oxazolone in 100 μL ethanol. Seven days after sensitization, P001009v1 was administered intravenously at a dose of 20 mg / kg. Four hours later, the thickness of both ears was measured. Then, both ears were sensitized with 2% oxazolone in 10 μL ethanol. The thickness of both ears was measured again at 24 and 48 hours, and changes in the thickness of ear edema were recorded. Statistical analysis was performed using one-way ANOVA.

[0544] As described in Figure 24, the antibody P001009v1 of the present invention exhibited a significant anti-inflammatory response compared to the control group. This efficacy trend was maintained even after 48 hours.

[0545]

[0546] The anti-CD200R1 antibody or antigen-binding fragment thereof of the present invention exhibits superior binding affinity to CD200R1 while non-competitively binding to human CD200 compared to existing anti-CD200R1 antibodies, and in particular, the anti-CD200R1 antibody or antigen-binding fragment thereof of the present invention exhibits excellent immunosuppression and inflammatory response inhibition effects, and thus can be usefully used for the prevention or treatment of immune diseases or inflammatory diseases.

[0547]

[0548] While specific aspects of the present invention have been described in detail above, it will be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.

[0549]

[0550] Electronic file attached.

Claims

1. An antibody or antigen-binding fragment thereof that specifically binds to CD200R1 comprising: A heavy chain CDR1 comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 8, SEQ ID NOs: 100 to 103, and SEQ ID NO: 158; A heavy chain CDR2 comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 9 to 21, SEQ ID NOs: 104 to 109, and SEQ ID NO: 159; A heavy chain CDR3 comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 22 to 35, SEQ ID NOs: 110 to 115, SEQ ID NOs: 160, SEQ ID NOs: 172 and 173; A light chain CDR1 comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 36 to 47, SEQ ID NOs: 116 to 122, SEQ ID NO: 161, SEQ ID NO: 192, and SEQ ID NO: 193; A light chain CDR2 comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 48 to 58, SEQ ID NOs: 123 to 127, SEQ ID NO: 162, and SEQ ID NO: 194; and A light chain CDR3 comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 59 to 70, SEQ ID NOs: 128 to 134, SEQ ID NOs: 163, SEQ ID NOs: 174 to 183, SEQ ID NOs: 195, and SEQ ID NOs:

196.

2. An antibody or antigen-binding fragment thereof, comprising a heavy chain variable region comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 71 to 85, SEQ ID NOs: 135 to 141, SEQ ID NOs: 149 to 153, SEQ ID NO: 184, and SEQ ID NO: 185, in the first paragraph.

3. An antibody or antigen-binding fragment thereof, comprising a light chain variable region comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 86 to 99, SEQ ID NOs: 142 to 148, SEQ ID NOs: 154 to 157, SEQ ID NOs: 186 to 191, and SEQ ID NOs: 197 to 200, according to claim 1.

4. In paragraph 1, an antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region selected from the group consisting of: - A heavy chain variable region of sequence number 71 and a light chain variable region of sequence number 86; - A heavy chain variable region of sequence number 72 and a light chain variable region of sequence number 87; - A heavy chain variable region of sequence number 73 and a light chain variable region of sequence number 88; - A heavy chain variable region of sequence number 74 and a light chain variable region of sequence number 89; - A heavy chain variable region of sequence number 75 and a light chain variable region of sequence number 90; - A heavy chain variable region of sequence number 76 and a light chain variable region of sequence number 91; - A heavy chain variable region of sequence number 77 and a light chain variable region of sequence number 92; - A heavy chain variable region of SEQ ID NO: 78 and a light chain variable region of SEQ ID NO: 93; - A heavy chain variable region of sequence number 79 and a light chain variable region of sequence number 94; - A heavy chain variable region of sequence number 80 and a light chain variable region of sequence number 95; - A heavy chain variable region of sequence number 81 and a light chain variable region of sequence number 96; - A heavy chain variable region of SEQ ID NO: 82 and a light chain variable region of SEQ ID NO: 97; - A heavy chain variable region of sequence number 83 and a light chain variable region of sequence number 98; - A heavy chain variable region of SEQ ID NO: 84 and a light chain variable region of SEQ ID NO: 94; - A heavy chain variable region of sequence number 85 and a light chain variable region of sequence number 99; - A heavy chain variable region of sequence number 135 and a light chain variable region of sequence number 142; - A heavy chain variable region of sequence number 136 and a light chain variable region of sequence number 143; - A heavy chain variable region of sequence number 137 and a light chain variable region of sequence number 144; - A heavy chain variable region of SEQ ID NO: 138 and a light chain variable region of SEQ ID NO: 145; - A heavy chain variable region of sequence number 139 and a light chain variable region of sequence number 146; - A heavy chain variable region of sequence number 140 and a light chain variable region of sequence number 147; - A heavy chain variable region of sequence number 141 and a light chain variable region of sequence number 148; - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 155; - A heavy chain variable region of sequence number 151 and a light chain variable region of sequence number 155; - A heavy chain variable region of SEQ ID NO: 152 and a light chain variable region of SEQ ID NO: 157; - A heavy chain variable region of SEQ ID NO: 153 and a light chain variable region of SEQ ID NO: 157; - A heavy chain variable region of sequence number 151 and a light chain variable region of sequence number 157; - A heavy chain variable region of sequence number 152 and a light chain variable region of sequence number 155; - A heavy chain variable region of SEQ ID NO: 184 and a light chain variable region of SEQ ID NO: 155; - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 186; - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 187; - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 188; - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 189; - A heavy chain variable region of sequence number 185 and a light chain variable region of sequence number 155; - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 190; - A heavy chain variable region of sequence number 185 and a light chain variable region of sequence number 186; - A heavy chain variable region of sequence number 185 and a light chain variable region of sequence number 187; - A heavy chain variable region of sequence number 150 and a light chain variable region of sequence number 191; - A heavy chain variable region of sequence number 185 and a light chain variable region of sequence number 190; - A heavy chain variable region of sequence number 185 and a light chain variable region of sequence number 191; - A heavy chain variable region of SEQ ID NO: 79 and a light chain variable region of SEQ ID NO: 197; - A heavy chain variable region of SEQ ID NO: 79 and a light chain variable region of SEQ ID NO: 198; - a heavy chain variable region of sequence number 79 and a light chain variable region of sequence number 199; and - A heavy chain variable region of sequence number 79 and a light chain variable region of sequence number 200.

5. An antibody or antigen-binding fragment thereof, comprising single-chain Fvs (scFv), single-chain antibodies, Fab, F(ab'), or disulfide-linked Fvs (sdFv) in the first paragraph.

6. In paragraph 5, the scFv comprises a heavy chain variable region comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 71 to 85, SEQ ID NOs: 135 to 141, SEQ ID NOs: 149 to 153, SEQ ID NOs: 184, and SEQ ID NOs: 185; and An antibody or antigen-binding fragment thereof, characterized in that a light chain variable region comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 86 to 99, 142 to 148, 154 to 157, 186 to 191, and 197 to 200 is connected via a linker.

7. A nucleic acid encoding an antibody or an antigen-binding fragment thereof according to any one of claims 1 to 6.

8. A recombinant expression vector containing the nucleic acid of Article 7.

9. A host cell transfected with the recombinant expression vector of Article 8.

10. A method for producing an antibody or an antigen-binding fragment thereof that specifically binds to CD200R1, comprising the steps of culturing the host cell of clause 9 to produce an antibody; and isolating and purifying the produced antibody.

11. A bispecific or multispecific antibody comprising an antibody or antigen-binding fragment thereof according to any one of claims 1 to 6.

12. A chimeric antigen receptor (CAR) comprising an extracellular domain, a transmembrane domain, and an intracellular signaling domain comprising an antigen binding site of any one of claims 1 to 6.

13. An immune cell into which the chimeric antigen receptor (CAR) of Article 12 has been introduced.

14. In claim 13, the immune cell is an immune cell that is a regulatory T cell.

15. A composition for preventing or treating an immune disease or inflammatory disease, comprising an antibody or an antigen-binding fragment thereof according to any one of claims 1 to 6, a bispecific or multispecific antibody comprising the antibody or an antigen-binding fragment thereof, a chimeric antigen receptor comprising the antibody or an antigen-binding fragment thereof, or an immune cell comprising the chimeric antigen receptor.

Citation Information

Patent Citations

  • CD200r agonist antibodies and uses thereof

    US20200087395A1

  • Multivalent antibodies and uses therefor

    WO2001077342A1

  • Bivalent, bispecific antibodies

    WO2009080251A1

  • Bivalent, bispecific antibodies

    WO2009080252A1

  • Bivalent, bispecific antibodies

    WO2009080253A1